Dataset a	KNG95	KNG01	FKO	NGY	KMM	NGN

Date (FY)	1995–1996	2001–2003	2003	2004	2011–2012	2013

Location b	KNG Pref.	KNG Pref.	FKO Pref.	NGY City	KMM Pref.	NGN Pref.

Line c	TSL	TSL	SSL	TSL	KSL	HSL

Number of trains d

 Daytime (7:00–22:00)	234	265	142	249	112	62

 Nighttime (22:00–7:00)	16	22	18	21	17	7

Method	Visit-Mail e	Visit-Mail e	Visit-Mail e	Interview	Visit-Visit e	Mail-Mail e

Housing type (DH; AB) f	DH	DH & AB	DH	DH	DH & AB	DH

Annoyance	unbearable	ICBEN g	ICBEN g	ICBEN g	ICBEN g	ICBEN g

Response proportion (%) h	72	57	66	58	45	45

Sample size	709	872	358	175	559	294


Country	Author	Setting	Number	Measure	Prevalence

Lesotho	Hollifield et al. 1990	Rural	356	DIS	23.5% F14.7% M

Zimbabawe	Abas & Broadhead, 1997	Urban	172	SSQ	15.7% F 1 month, 30.8% F 1 year

South Africa	Haavenaar et al. 2008	Periurban	209	SRQ	34.9% M and F

South Africa	Haavenaar et al. 2008	Rural	222	SRQ	27.0% M and F

South Africa	Hamad et al. 2008	Urban	257	CES-D	64.5% F, 50.4 % M

Nigeria	Gureje et al. 2006	Probability sample of 8 states	4,984	CIDI	12.1% life time; 5.8% 12 month prevalence M and F

Ethiopia	Tafari et al. 1991	Rural	2,000	SRQ	11.2% M and F

Uganda	Orley and Wing 1979	Rural		PSE

Sudan	Rahim and Cederblad	Urban		SRQ/DSM III	16.6% M and F


Test	 	Positives (%)	Negatives (%)

T=3months

Culture (N=305)	Eradication	11 (7)	141 (93)

 	Placebo	99 (65)	54 (35)

H&E stains (N=305)	Eradication	19 (12)	133 (88)

 	Placebo	112 (73)	41 (27)

IHC stains (N=68)	Eradication	29 (85)	5 (15)

 	Placebo	7 (20)	27 (79)

Serology (N=203)	Eradication	92 (91)	9 (9)

 	Placebo	94 (92)	8 (8)

T=12months

Serology (N=304)	Eradication	96 (64)	55 (36)

 	Placebo	138 (90)	15 (10)


Hyperparameter	Value	Number of Occurrences

criterion	entropy	7

	gini	37

max_features	0.1	4

	0.25	5

	0.5	7

	0.75	15

	log2	2

	sqrt	2

	null	9

n_estimators	10	3

	100	17

	50	16

	500	6


ID	Position*	Tm
(°C)	Sequence (5′→3′)	Size (bp)

MYOC1	353–509	62	F: GGCTGGCTCCCC AGTATATA	174

			R: ACAGCTGGCATCTCAGGC

MYOC2	491–658	62	F: ACG TTG CTG CAG CTT TGG	196

			R: GATGACTGACATGGCCTGG

MYOC3	603–772	65	F: AGTGGCCGATGCCAGTATAC	189

			R: CTGGTCCAAGGTCAATTGGT

MYOC4	670–864	62	F: AGGCCATGTCAGTCATCCAT	214

			R: TCTCTGGTTTGGGTTTCCAG

MYOC5	778–958	60	F: TGACCTTGGACCAGGCTG	200

			R: CCTGGCCAGATTCTCATTTT

MYOC6	928–1095	63	F: TGGAGGAAGAGAAGAAGCGA	187

			R: CTGCTGAACTCAGAGTCCCC

MYOC7	1416–1630	62	F: AACATAGTCAATCCTTGGGCC	230

			R: TAAAGACCATGTGGGCACA

MYOC8	1933–2091	60	F: TTATGGATTAAGTGGTGCTTCG	177

			R: ATTCTCCACGTGGTCTCCTG

MYOC9	2069–2232	64	F: AAGCCCACCTACCCCTACAC	184

			R: AATAGAGGCTCCCCGAGTACA

MYOC10	2195–2366	64	F: ATACTGCCTAGGCCACTGGA	190

			R: CAATGTCCGTGTAGCCACC

MYOC11	2335–2512	63	F: TGGCTACCACGGACAGTTC	197

			R: CATTGGCGACTGACTGCTTA

MYOC12	2480–2653	64	F: GAACTCGAACAAACCTGGGA	195

			R: CATGCTGCTGTACTTATAGCGG

MYOC13	2624–2783	62	F: AGCAAGACCCTGACCATCC	179

			R: AGCATCTCCTTCTGCCATTG


Study	Status	Results	NCT identifier

Sorafenib versus placebo + FOLFOX or FOLFORI in the second-line treatment of colorectal cancer	Recruiting	Pending	NCT00889343

Sorafenib + capecitabine in patients with pretreated advanced CRC	Recruiting	Pending	NCT01290926

BAY 43-9006 plus cetuximab to treat colorectal cancer	Recruiting	Pending	NCT00326495

Sorafenib + FOLFORI in CRC after failure of oxaliplatin therapy	Recruiting	Pending	NCT00839111

Sorafenib + capecitabine in previously treated CRC	Recruiting	Pending	NCT01471353

Sorafenib + irinotecan in metastatic CRC and KRAS mutation	Completed	Pending	NCT00989469

Sorafenib, cetuximab, and irinotecan in treating patients with mCRC	Ongoing, not recruiting	Pending	NCT00134069

Sorafenib and bevacizumab versus single agent bevacizumab	Ongoing, not recruiting	Pending	NCT00826540

External-Beam radiation therapy, capecitabine, and sorafenib in treating patients with locally advanced rectal cancer	Recruiting	Pending	NCT00869570


Organism	Gene targeted	Primer Sequences 5' - > 3'	Amplicon size (bp)	Reference

A. phagocytophilum	ankA	F: CTATCATCCTTGGGTAGTGGCCT	223	This study

R: CTTCTGGTGTTCTCGGACCTTC

gltA	F: ATATCTACCGGAACCCCCATAGC	209

R: AAAAGCTATGACCCTAGAGCGCGT

groEL	F: GTGATTCGCACGCTCTTAGCAGT	172

R: GCCTTCAAGTTGCTGCTGTAAA

Bos taurus	gapdh	F: TTCACACTCTCCTTCCAGGTACG	217	[30]

R: TCAGGGCCTTAGAGATGGAAA

ywhaz	F: TACTCCGGACACAGGTAAGGGAC	212

R: AGAACCCAGCGGAAGAGAAG

ppia	F: CTGTTCTAGGTTGGATGGCAAGC	137

		R: TTTGTCCACAGTCAGCAATGGTGA


Study report	Location	Source of cases	Number of cases	Source of comparison group without diarrhoea	Matching of comparison group	Number of children without diarrhoea

Bangladesh 1992a [16]	Matlab (rural)	Active household surveillance	Varied by pathogen (68 – 184)	Same community study cohort	Age and proximity of residence	Varied by pathogen (67 – 164)

Bangladesh 1992b [17]	Mirzapur (rural)	Active household surveillance	Varied by pathogen (53 – 153)	Same community study cohort	Age and proximity of residence	Varied by pathogen (46 – 213)

India 1989 [18]	New Delhi	Hospital admissions	92	Other wards with non-gastro-intestinal illnesses	Age and nutritional status	92

India 1992 [19]	New Delhi	Hospital admissions	81	Nutrition clinic with failure to thrive and weight for height = 90% of standard	Not matched	32

India 1999 [22]	Slum of New Delhi	Active household surveillance	115	Same community study cohort	Age, nutritional status and proximity of residence	115

Brazil 1990 [26]	Urban slum, Fortaleza	Active household surveillance	40	Same community study cohort	Not matched	38

Brazil 1995 [29]	Fortaleza	Hospital admissions	56	Children on other wards	By age	42

Brazil 2000 [4]	Shanty town, Fortaleza	Active household surveillance	88	Same community study cohort	By age and sex	443


Dependent variable	Acute MI	Genotype	Acute MI × Genotype

 	F	p	Partial Eta squared	F	p	Partial Eta squared	F	p	Partial Eta squared

Serum ACE2 Levels	19.22	0.00	0.29	1.69	0.19	0.04	11.98	0.00	0.16


	Early remission n = 387	Arm 1 n = 83	Arm 2 n = 78	OOP n = 50

Patients with AE*, n (%)	205/387 (53 %)	53/83 (64 %)	52/78 (67 %)	27/50 (54 %)

Total number of AE	408	129	109	58

Cardiovascular	25	5	8	4

Pulmonary	17	5	2	2

Gastrointestinal	67	16	14	12

GI complaints	8	2	2	–

 Nausea/emesis	23	2	4	4

 Increased liver enzymes	15	7	3	4

 Other	21	5	5	4

Neuro-psychiatric	37	5	7	3

 Headache	14	–	4	1

 Dizziness	7	1	–	1

 Mood disorders	4	–	–	1

 Other	12	4	3	–

Urogenital	7	3	2	3

Skin/mucous membranes	45	18	15	3

 Rash	19	8	5	–

 Hair loss/thinning	4	1	1	1

 Sicca complaints	3	–	–	1

 Eczema	3	1	–	–

 Other	16	8	9	1

Infections	106	38	41	18

 Upper airway tract	29	11	16	10

 Gastrointestinal	4	1	–	2

 Skin/mucosa	14	2	4	2

 Pneumonia/bronchitis	9	1	1	1

 Urinary tract	15	7	5	1

 Influenza/unspecified fever	25	10	6	1

 Other	10	6	9	1

Trauma/injury	13	5	2	3

Infusion reaction	3	1	–	–

Malaise	9	5	1	1

Surgical procedures without hospitalization	13	5	4	1

Other	65	23	12	8


Test	Meaning	P-value

1 vs. only fixed effects	QTL additive effect	6 × 10-7

2 vs. 0	QTL additive effect conditional on infinitesimal effect	3 × 10-7

3 vs. 0	QTL additive and dominance effects conditional on infinitesimal effect	2 × 10-6

4 vs. 0	QTL additive effect nested within sex conditional on infinitesimal effect	3 × 10-8

5 vs. 0	Raw association signal conditional on infinitesimal effect	5 × 10-7

6 vs. 4	Association (SNP) signal conditional on linkage (QTL) signal	0.43

6 vs. 5	Linkage signal conditional on SNP signal	7 × 10-3


Direct costs of NSIs

Testing for blood-borne viruses [6,26-30] in:

NSI recipient – initial test	€38.76

NSI recipient – follow-up test	€58.52

Source patient (if known)	€43.91

Cost of staffing and administration per NSI [26,31]	€68.81

Cost of PEP for hepatitis B and HIV [19,25,32,33] per:

NSI from a known and infected source	€374.61

NSI from an unknown source	€918.76

Cost of treatment of blood-borne viruses [19,25,34-38]:	€2,377.44

Hepatitis B (year in which NSI occurred and per subsequent year for three years)

Hepatitis C (year in which NSI occurred only)	€16,127.76

HIV (year in which NSI occurred and per subsequent year)	€16,999.83


Number of free nicotine patches provided	Group 12-week supply	Group 24-week supply	Group 36-week supply contingent upon first 2-weeks of use	Group 46-week supply	Group 58-week supply

12-month quit rate*	31.0%	21.0%	15.5%	37.8%	31.1%

12-month intent-to-treat quit rate**	19.1%	12.9%	7.0%	23.1%	22.6%

Sustained quitters*	24.6%	20.3%	11.7%	27.3%	19.9%

Relapsed smokers*	18.9%	14.9%	16.4%	11.9%	10.2%

Delayed quitters*	6.4%	0.7%	3.8%	10.5%	11.3%


	mNCV	CMAP

Patient 1	39 m/s	3.4 mV

Patient 2	45 m/s	4.0 mV

Patient 3	32 m/s	1.5 mV

Patient 4	32.4 m/s	5.1 mV

Patient 5	34.1 m/s	1.4 mV


Length	Coefficient	Std. Err.	z	P > z	[95% Conf.	Interval]

Days	−0.1 mm	0.1 mm	−1.16	0.25	−.4 mm	.1 mm

Female vs. Male	18 mm	3 mm	5.59	0.000	11 mm	24 mm

Right vs. Left	0 mm	3 mm	−0.15	0.88	−6 mm	5 mm

Displaced	−9 mm	4 mm	−2.19	0.03	−16 mm	0 mm

Mid vs. Lateral	1 mm	4 mm	0.38	0.70	−6 mm	8 mm

Interaction displaced/time

 Displaced over time	0 mm	0.1 mm	0.61	0.54	−0.2 mm	0.4 mm

 Length constant	137 mm	5 mm	28.14	0.000	127 mm	147 mm


	Model 2

	Coefficient	SE	P > |z|

Salary	0.00006	9.79e − 06	0.000

Salary*health professionals	0.00001	0.00001	0.217

Place of work: district capital	−0.01274	0.08298	0.878

Place of work: district capital*health professionals	−0.46284	0.10504	0.000

Place of work: provincial capital	0.10538	0.06535	0.107

Place of work: provincial capital*health professionals	−0.30624	0.07642	0.000

Housing	0.53866	0.06060	0.000

Housing*health professionals	0.00126	0.07085	0.986

Access to a loan	0.38210	0.05889	0.000

Access to a loan*health professionals	−0.07671	0.06722	0.254

Formal education	0.51927	0.06637	0.000

Formal education*health professionals	−0.00102	0.07890	0.990

Skills development	0.26677	0.04949	0.000

Skills development*health professionals	0.01989	0.05856	0.734

Availability of equipment and medicine	0.25184	0.05697	0.000

Availability of equipment and medicine*health professionals	0.12082	0.06803	0.076

Private practice	0.10305	0.04295	0.016

Private practice*health professionals	−0.02353	0.05097	0.644

Const	−0.02475	0.02854	0.386

Number of groups	455

Number of observations	14 408

Log likelihood	−4 269.1452

Wald chi-square	919.02

Prob > chi-square	0.0000


Group	Operation	Treatment	Dose	Frequency	n

 	 	 	 	(μg·kg−1)	(μg·kg−1 per week)

1	Sham	Sham	Vehicle	—	—	3/week	5

2	W3V	OVX	Vehicle	—	—	3/week	5

3	W3M	OVX	TPTD	6	18	3/week	5

4	W3H	OVX	TPTD	30	90	3/week	5

5	D1V	OVX	Vehicle	—	—	1/day	5

6	D1L	OVX	TPTD	1.2	8.4	1/day	5

7	D1M	OVX	TPTD	6	42	1/day	5

8	D1H	OVX	TPTD	30	210	1/day	5

9	D2V	OVX	Vehicle	—	—	2/day	5

10	D2L	OVX	TPTD	1.2	16.8	2/day	5

11	D2M	OVX	TPTD	6	84	2/day	5

12	D2H	OVX	TPTD	30	420	2/day	5

13	D3V	OVX	Vehicle	—	—	3/day	5

14	D3L	OVX	TPTD	1.2	25.2	3/day	5

15	D3M	OVX	TPTD	6	126	3/day	5


Patient details	Preoperative data	Data prior to withdrawal of epidural catheter

Age	Time of epidural catheterization	Time of withdrawal of epidural catheter

Sex	Time of blood testing	Time of blood testing

Epidural or intravenous analgesia	Activated partial thromboplastin time (aPTT)	Time and dosage of the last dose of low molecular weight heparin (LMWH) before withdrawal of epidural catheter

Reason for intravenous analgesia if applicable	Prothrombin time international normalised ratio (PT-INR)	Activated partial thromboplastin time (aPTT)

Level of epidural catheterization	Platelet count (Plc)	Prothrombin time international normalised ratio (PT-INR)

Blood haemoglobin level (Hb)	Platelet count (Plc)

Serum albumin (Alb)	Blood haemoglobin level (Hb)

Serum creatinine (Crea)


Target population	Approach	Number conducted	Target population reached

Male and female adolescents	FGD	6	48

Women with children under 5 years	FGD	6	32

Men whose children have or have not been involved in any study conducted by KHRC	FGD	6	37

Women 45 years+	FGD	6	43

Traditional leaders	IDI	2	2

Assembly men and women and government appointees.	IDI	12	12

Head of district commission for human rights and administrative justice.	IDI	1	1

District Information officer.	IDI	1	1

Church leaders	IDI	2	2

Ghana Private Road Transport Union (GPRTU ) Official	IDI	1	1

Health professionals	IDI	3	3

Traditional healer	IDI	1	1

Director of Agriculture	IDI	1	1

Unit committee members.	IDI	1	1

Chemical drug sellers	IDI	2	2

Ghana Police personnel	IDI	2	2

Community members	Radio discussions	7	~52,000

Community members	Community durbars	33	~86,700

Assembly members, the media, health professionals and other government organizations	Workshops	5	145


Landmarks	Lee et al. [13] Mean (mm) ± SD	Lee [16] Mean (mm) ± SD

Height of maxillary sinus roof	33.45 ± 2.83	33.83 ± 3.40

Maxillary sinus roof to posterior ethmoid roof	14.08 ± 3.03	Not measured

Maxillary sinus roof to sphenoid ostium	2.76 ± 2.80	1.79 ± 3.09

Maxillary sinus roof to sphenoid roof	12.18 ± 3.20	12.02 ± 2.93

Maxillary sinus roof to sphenoid floor	5.94 ± 2.94	6.18 ± 2.88


Variable	Coefficient	P

Prior history of radiation	−1.350	.012

Volume per injection, mL	2.060	.094


Drug	Disease	NCT number	Phase

5-Azacitidine	Beta thalassemia	NCT00005934	Phase 2

5-Azacytidine + Na phenylbutyrate	Thalassemia major	NCT00007072	Phase 2

Resveratrol	Cardiovascular diseases	NCT01449110	Phase 2

Resveratrol	Trauma	NCT01321151	Phase 1

Resveratrol	Metabolic syndrome, obesity	NCT01150955	Phase 1

Curcumin	Irritable bowel syndrome	NCT00779493	Phase 4

Curcumin	Alzheimer disease	NCT00164749	Phase 2

Curcumin	Psoriasis	NCT00235625	Phase 2


	Assessment Period

Measure	E1	E2	2 weeks	6 weeks	13-weeks	6 month	1 year	2 years

Height, weight	Monthly	Every 3 months

DXA		X			X	X	X	X

Waist Circumference	Monthly	Every 3 months

Blood Pressure				X	X	X	X	X

Aerobic fitness		X			X	X	X	X

Strength fitness		X			X	X	X	X

ActicalTM		X			X	X	X	X

7-day PAR		X			X	X	X	X

Ultrasound		X			X	X	X	X

EKG		X			X	X	X	X

PAT	X					X	X	X

Blood work	X					X	X	X

3-day food records				X	X	X	X	X

Quality of Life		X			X	X	X	X

Social Support		X			X	X	X	X

Outcome Expectations		X		X	X	X	X	X

Satisfaction		X		X	X	X	X	X

Enjoyment		X		X	X	X	X	X

Self-efficacy			X	X	X	X	X	X

Group Cohesion			X		X

Collaboration			X		X

Intentions			X	X	X	X	X	X


Patient	Age/years	LH (mIU/ml)	FSH (mIU/ml)	Prolactin (ng/ml)	Estradiol (pg/ml)	Progesterone (ng/ml)	Testosterone (ng/ml)	Follicle numbers	Clinical information

F1‐II1	34	6.58	17.49↑	19.55	40	0.15	0.85	Left: 5, Right: 10	BPES; Menarche 16 years; irregular cycles

F2‐II1	30	10.33	17.84↑	7.16	42	0.2	0.59	Left: 2, Right: 3	BPES; Menarche 15 years; irregular cycles


Survival	MYC CNA+ and MYC-R+	MYC-R+ alone	MYC CNA+ alone

	χ2	P value	χ2	P value	χ2	P value

Overall survival

MYC CNA+ and MYC-R+			2.819	0.093	0.066	0.797

MYC-R+ alone	2.819	0.093			0.339	0.560

MYC CNA+ alone	0.066	0.797	0.339	0.560

Progression-free survival

MYC CNA+ and MYC-R+			3.481	0.062	4.499	0.034

MYC-R+ alone	3.481	0.062			3.400	0.054

MYC CNA+ alone	4.499	0.034	3.400	0.054


Characteristics	Cases	CD40 mutant expression	χ2	P

Positive	Negative

Sex

Male	58	33	25	0.286	0.593

Female	20	10	10

Age (years)

≥60	48	36	12	2.849	0.091

<60	30	17	13

Tumor size (cm)

≥5	37	20	17	0.033	0.856

<5	41	23	18

Differentiation

Well/moderate	43	20	23	2.074	0.15

Poor	35	22	13

Depth of tumor invasion

Not to deep muscle layer	10	1	9	9.444	0.002a

Deep muscle layer	68	42	26

Lymph nodes metastasis

Yes	60	39	21	7.802	0.005a

No	18	5	13

TNM stage

I and II	17	4	13	8.774	0.003a

III and IV	61	39	22


 	N	%

Total number of patients	14

Age

Median (Range)	69.5 (38–88)

Gender

Male	9	64

Female	5	36

Race

White	14	100

Performance Status (PS)

0	7	50

1	7	50

Extra-lymphatic sites involved

0	8	57

1	1	7

2	3	21

>2	2	14

Elevated LDH	6	43

Bone Marrow Involvement	1	7

B symptom	0	0

Mediastinal mass	0	0

Lymph node or aggregate with a diameter >5 cm	5	36

Prior Treatment

Prior Chemotherapy	14	100

Prior Immunotherapy	4	29

Prior Radiation Therapy	4	29

Prior Surgery (with therapeutic intent)	1	7

Prior Bone Marrow Transplant*	3	21

Other Prior Therapy**	1	7


Protein	Gene symbol	Gene ID	Sequence 5′- 3′ F	Sequence 5′- 3′ R

Lipocalin2	Lcn2	16819	ATATGCACAGGTATCCTCAG	GAAACGTTCCTTCAGTTCAG

CD163	Cd163	93671	AGTCTGCTCACGATACATAG	TCCTTCTGGAATAGATTGGG


	Years	Survival rate (%)	95% confidence interval

Overall survival	2	90	80; 100

	3	78	64; 96

	5	69	53; 90

Disease-free survival	2	85	72; 100

	3	85	72; 100

	5	79	65; 98


Score	Symptoms

Grade 1	Local paraesthesia (anesthesia, tingling, stinging)

Grade 2	Hypersecretion (sweat, saliva)

Grade 3	Impaired vision, hearing, speech, dysphagia

Grade 4	Bilateral ptosis

Grade 5	Severe dyspnea

Grade 6	Severe consciousness disorders, motor and respiratory paralysis


Cell type	Species	Passage	Culture method	Reference

Chondrocyte	Human	P2	Monolayer + 3D	[7]

ADSC	Human	P4	Monolayer + 3D	[8]

SDSC	Human	P2	Monolayer + 3D	[11]

BMSC	Human	P2	Monolayer + 3D	[11]

Chondrocyte	Human	P2	Monolayer	[11]

Chondrocyte	Rabbit	P0-P4	Monolayer	[12]

Chondrocyte	Human	P0-P4	Monolayer	[13]

SDSC	Human	P4-P7	Monolayer + 3D	[14]

Chondrocyte	Human	P0-P4	Monolayer + 3D	[15]

BMSC	Human	P1-P4	Monolayer + 3D	[15]


	Library name

	AA9	B421	CHORI-514	MCF7	PM-1	CHORI-510	CHORI-518	CHORI-520

Clinical sample designation	AA9	B421	S104	MCF-7	25-48	860-7	BT-474	SK-BR-3

Organ site	Brain	Breast	Breast	Breast cancer adenocarcinoma (metastasis - pleural effusion)	Prostate metastasis	Ovarian carcinoma	Ductal carcinoma	Breast cancer adenocarcinoma (metastasis - pleural effusion)

Therapies applied	Radiotherapy	Chemotherapy 4 months before surgery (CMF)	No radiation therapy or chemotherapy before surgery	N/A	Hormone ablation, palliative radiotherapy	No therapy before surgery	N/A	N/A

Patient status	Deceased	Deceased, no recurrence	No recurrence for 10 years	N/A	Deceased	Tumor recurred within 13 months	N/A	N/A

Total amount of tumor material used for library construction (mg)	100	150 (20 mg effective)	100	N/A	50	200	N/A	N/A

Average clone size (± standard deviation; kb)	129.1 ± 38.3	136.4 ± 29.2	166.1 ± 53.2	148.0 ± 30	N/D	149.3 ± 28.8	179 ± 23	154 ± 25


Gene	Cell locale	Tissue	Modality of expression

HSPA8	Cytosol. Translocate to nucleus and nucleoli upon heat shock. Surface of embryonic stem cells	Highly expressed in all tisuses	Constitutive. Moderately induced by heat shock

HSPA2	Nucleus	Mostly in testis, skeletal and heart muscles, esophagous, brain	Constitutive

HSPA1A and HSPA1B	Cytosol. Nucleus and nucleoli upon heat shock	All tissues	Strongly induced by heat shock

HSPA1L	Mostly cytosol under basal conditions. Nucleus but not nucleoli upon heat shock	Spermatides	Constitutive. Not induced by heat shock

HSPA6	Cytosol. Nucleus	Most tissues	Induced by heat shock. No basal expression

HSPA5	Endoplasmic reticulum (ER)	All tissue	Induced by ER stressors

HSPA9B	Mitochondria. ER. Cytosol. Cytosolic vesicles. Membrane surface	Many tissues	Constitutive

STCH	Microsomas	All tissues	Constitutive

HSPA14	Cytosol. Associated to ribosomes	Many tissues (low expression)	Undetermined

HSPA4	Cytosolic (?)	Most tissues	Constitutive. Not induced by heat shock

HSPA4L	Cytosol. Nucleus upon heat shock	Mostly testis	Constitutive. Induced by heat shock in somatic cells but not in germ cells

HSPH1	Cytosol. Nucleus upon heat shock, possibly nucleoli	Most tissues	Constitutive. Induced by heat shock

HYOU1	ER. Cytosol (isoform 3)	Liver, pancreas. Highly expressed in cells with well developed ER	Induced by ER stressors

HSPA12A	Undetermined yet	Brain. Kidney. Muscle	Constitutive. Induced by stress

HSPA12B	Undetermined yet	Skeletal and heart muscles	Constitutive. Induced by stress


Study (reference)	Patients	Molecular marker	Ethnicity (Country)	Evaluation criteria	Sample size	Chemotherapeutic regimens	Outcomes

Goekkurt 2006, [11]	Patients with advanced GC	TS, GSTs, MTHFR, ERCC1-118	European (Germany)	RECIST	52	5-Fu+cisplatin + leucovorin	RR and OS

Ruzzo 2006 [14]	Patients with advanced GC	TS, GSTs, MTHFR, ERCC1-118	European (Italy)	Others	175	fluorouracil/cisplatin	RR and OS

Shim 2010 [17]	Patients with recurrent or metastatic GC	GSTs	Asian (Korea)	RECIST	200	Paclitaxel/docetaxel +cisplatin	RR and OS

Park 2011 [18]	Patients with metastatic GC	ERCC1-118	Asian (Korea)	RECIST	108	S-1 + cisplatin	RR and OS

Han 2010 [19]	Patients with recurrent or metastatic GC	TS, ERCC1-118	Asian (Korea)	RECIST	38	5-Fu+leucovorin +oxaliplatin	RR and OS

Stocker 2009 [20]	Neoadjuvant chemotherapy for locally advanced GC without distant metastasis	ERCC1-118	European (Germany)	Others	178	5-Fu+leucovorin +cisplatin	RR and OS

Seo 2009 [21]	Patients with recurrent or metastatic GC	TS, GSTs, ERCC1-118	Asian (Korea)	RECIST	94	5-Fu+ oxaliplatin/irinotecan	RR, OS and toxicity

Liu 2011 [22]	Patients with advanced GC	GSTs, ERCC1-118	Asian (China)	NR	126	5-FU+leucovorin +oxaliplatin	OS

Ott 2008 [23]	Neoadjuvant chemotherapy for locally advanced GC without distant metastasis	GSTs	European (Germany)	Others	139	5-Fu+leucovorin + cisplatin	RR and OS

Li 2010 [24]	Patients with advanced GC	GSTs	Asian (China)	Others	92	5-Fu +oxaliplatin	RR, OS and toxicity

Lu 2004 [25]	Patients with advanced GC	MTHFR	Asian (China)	WHO	75	5-Fu+leucovorin	RR and toxicity

Huang 2009 [26]	Patients with GC after curative surgery	GSTs, ERCC1-118	Asian (China)	NR	102	5-Fu+leucovorin +oxaliplatin	OS

Shitara 2010 [27]	Patients with inoperable GC	TS, MTHFR	Asian (Japan)	NR	132	5-Fu et al.	OS and toxicity

Huang 2009 [28]	Patients with GC after curative surgery	TS, MTHFR	Asian (China)	NR	116	5-Fu+leucovorin et al.	OS

Ishida 2002 [29]	Patients with GC after surgery	TS	Asian (Japan)	NR	51	5-Fu et al.	OS

Keam 2008 [30]	Patients with recurrent or metastatic GC	GSTs, ERCC1-118	Asian (Korea)	WHO	73	5-Fu+leucovorin +oxaliplatin	RR and OS

Goekkurt 2009, [31]	Patients with advanced GC	TS, GSTs, MTHFR, ERCC1-118	European (Germany)	Others	134	5-Fu+leucovorin +oxaliplatin/cisplatin	RR, OS and toxicity

Ott 2006 [32]	Neoadjuvant chemotherapy for patients with locally advanced GC	TS, MTHFR	European (Germany)	Others	135	5-Fu+cisplatin	RR and OS

Ott 2011 [33]	Neoadjuvant chemotherapy for patients with locally advanced GC	MTHFR	European (Germany)	Others	144	5-Fu+leucovorin + cisplatin	OS

Lee 2005 [34]	Patients with advanced GC	TS, MTHFR	Asian (Korea)	NR	25	5-Fu et al.	OS


 	Median total number of lymph nodes for patients with nodal involvement	Median total number of lymph nodes for patients without nodal involvement	P-value

PCG	13.0 (10–17)*	14.0 (11–18)*	0.654

 	PCG	PSG

Median number of involved lymph nodes	3.0 (1–6)*	2.5 (1–5)*	0.904


Sample	CO (μmol·g−1)

Anhydride	Phenol	Carbonyl and Quinone	Pyrone and Chromene

RN1	–	–	380	620

RN1P	–	–	14	140

RN1A	137		1310	–

RN2	–	52	60	800

RN2D5	–	32	–	250

RN2D10	–	–	30	270


Indication	Number

Renal impairment and acidosis	20

Renal impairment and hyperkalaemia	0

Renal impairment, acidosis and hyperkalaemia	6

Renal impairment, acidosis and convulsions	2

Renal impairment, acidosis, hyperkalaemia and convulsions	3

Worsening renal function despite conservative measures	5

Worsening renal function and convulsions	1

Renal impairment and pulmonary oedema	1

Renal impairment, acidosis and pulmonary oedema	1

Total	39


Class of agent	Chemical/brand name	Preventive targets

Selective estrogen receptor modulators and other hormonal agents	Tamoxifen	Breast

Arzoxifene	Breast

Acolbifene	Breast

Raxoxifene/Evista®	Breast

Finasteride	Prostate

Nonsteroidal anti- inflammatory drugs	Celecoxib/Celebrex®	Colon, breast, prostate, bladder

Sulindac/Clinoril®	Esophagus, skin

Aspirin

Minerals and micronutrients	Calcium compounds	Colon

Glucocorticoids	Budesonide	Lung

Retinoids	All-trans-retinoic acid tretinoin/Retin-A®	Cervix, esophagus, larynx, lung,

 	9-cis-Retinoic acid alitretinoin/Panretin®	Nasopharynx, oral cavity, ovary

 	13-cis-Retinoic acid isotreninoin/Accutane®

 	4-Hydroxyretinamide, (4-HPR) fenretinide


	Authors	Publication year	Patient number	Gender	Age	Open (O) or laparoscopic ablation (L)	Symptom related to lymphangioma	Left/right adrenal gland

1	Akand et al. [6]	2013	1	F	44	O	Pain	L

2	Sourial et al. [7]	2013	1	F	52	L	Nihil	L

3	Makni et al. [12]	2012	2	F/M	40/40	O/L	Nihil/pain	2 L

4	Ellis et al. [2]	2011	9	6 F/3 M	28 to 56a	Not precised	5 Nihil/4 pain	6 R/3 L

5	Chien et al. [13]	2008	8	6 F/2 M	31 to 59a	Not precised	4 Nihil/2 pain/1 fever/1 HTNb	4 R/4 L

6	Bettaïeb et al. [8]	2007	1	F	22	Not precised	Pain	L

7	Ates et al. [9]	2005	1	F	26	O	Weakness	R

8	Garcia et al. [10]	2004	1	F	22	Not precised	Pain	R

9	Longo et al. [11]	2000	1	F	30	O	Pain	R

10	Trojan et al. [3]	2000	1	M	40	Not precised	Nihil	R


	Mean	Median	Inter-quartile range	Direct cost as % of total cost of illness

Total CNCD sample (n = 475)	1040.82	40	(1000, 0)	56.8 %

Chronic pain conditions (n = 126)	926.92	200	(1268, 0)	51.6 %

Chronic respiratory conditions (n = 98)	623.60	0	(900, 0)	60.8 %

Chronic cardiovascular conditions (n = 95)	1723.99	200	(1600, 0)	54.0 %

Chronic sense organ conditions (n = 65)	465.35	0	(357, 0)	66.4 %

Chronic neuropsychiatric conditions (n = 47)	1465.64	50	(951, 0)	65.2 %

Chronic digestive conditions (n = 42)	929.05	70	(1268, 0)	53.3 %


GenBank accession no.	Gene name	Gene symbol	Fold change (HN2/control)a	Summary function

Highest response to HN2

 BG080773	AMP deaminase 3	Ampd3	4.10	Purine metabolism

 BG066562	proteasome (prosome, macropain) 26S subunit, non-ATPase, 7	Psmd7	3.86	Protein degradation

 C87546	serine/threonine kinase 11	Stk11	3.83	Cell cycle and polarity

 BG086264	polymerase (RNA) II, DNA directed	Polr2	–3.27	RNA synthesis

Neuronal function

 AI850277	neuromedin	Nmu	2.03	Locomotor and stress response

 A1848307	staufen homolog 2	Stauf2	–2.14	RNA transport

 AI847890	proteolipid protein	Plp	–2.16	Myelination

Development

 BG088163	split hand/foot deleted gene 1	Shfdg1	3.08	DNA repair

 AU021923	jagged 1	Jag1	2.61	Oligodendrocyte development

 BG063365	chemokine (C-X-C motif) receptor 4	Cxcr4	2.39	Neural progenitors

 AI847007	NCK-associated protein 1	Nckap1	–2.02	Cell motility

 AI843136	N-myc downstream regulated 2	Ndr2	–2.23	Neural differentiation

Apoptosis control

 C85471	programmed cell death 8	Pdcd8	2.69	Apoptosis control

 BG086831	programmed cell death 4	Pdcd4	2.13	Apoptosis control

 AI853558	tumor necrosis factor receptor superfamily, member 12a	Tnfrsf12a	–2.11	Nuclear factor-kappaB activation

Ubiquitin-proteasome pathway

 BG085363	proteasome (prosome, macropain) 26S subunit, non-ATPase, 11	Psmd11	2.71	Proteasome (19S Lid)

 AI843127	huntingtin interacting protein 2	Hip2	2.11	Ubiqutiin-conjugating enzyme

 AU020960	proteaseome (prosome, macropain) 28 subunit, 3	Psme3	–2.41	Proteasome (20S alpha subunit)

Growth and cell cycle control

 C86021	growth differentiation factor 9	Gdf9	3.61	Cell growth

 AI853288	ras homolog gene family, member U	Arhu	2.33	Signal transduction

 BG072244	calmodulin 1	Calm1	2.13	Cell cycle

 AI843756	calmodulin 2	Calm2	–2.16	Cell cycle

Miscellaneous genes of interest

 AI851097	H1 histone family, member 2	H1f2	–2.36	Chromatin compaction

 AI849019	myelin-associated oligodendrocytic basic protein	Mobp	–2.71	Stuctural components of myelin


Type	Number of reads	Percentage (%)

Total unique reads	9,664,154	100

Reads mapping to the transcripts	9,193,054	95.13

Reads mapping to target site	6,916	0.072

Total Number of input cDNAs	77,024	100

Number of covered cDNAs	43,648	56.65


 	Trial	N, inclusion criteria	Dose (dose per fraction)	Outcome

Early hypofractionation trials	Lukka et al. [44]	936GS 6–10	52.5 Gy (2.625 Gy)66 Gy (2 Gy)	40% versus 43% 5-year freedom from biochemical failure

Yeoh et al. [45]	217	55 Gy (2.75 Gy)64 Gy (2 Gy)	53% versus 34% 7-year freedom from biochemical failure

Modern superiority trials	Hoffman et al. [47]	20499% low-intermediate risk	72 Gy (2.4 Gy)75.6 Gy (1.8 Gy)	96% versus 92% 5-year freedom from biochemical failure

Pollack et al. [49]	303GS 6+	70.2 Gy (2.7 Gy)78 Gy (2.17 Gy)	23% versus 21% 5-year biochemical or clinical disease failure

Arcangeli et al. [48]	168GS 7+	62 Gy (3.1 Gy)80 Gy (2 Gy)	85% versus 79% 5-year freedom from biochemical failure

Modern noninferiority trials	Dearnaley et al. [46]	457	57 Gy (3 Gy)60 Gy (3 Gy)74 Gy (2 Gy)	Similar GU and GI toxicity ≥ grade 2 (<5%)

Incrocci [52]	820Intermediate-high risk	64.6 Gy (3.4 Gy)78 Gy (2 Gy)	Worse GI toxicity ≥ grade 2, similar GU toxicity

RTOG 0415 [51]	1101Low risk	70 Gy (2.5 Gy)73.8 Gy (1.8 Gy)	Noninferior biochemical recurrence and overall survival, similar toxicity

PROFIT [53]	Intermediate risk	60 Gy (3 Gy)78 Gy (2 Gy)	Pending


Implicit review process measure	Acceptable care*	Extremely appropriate care**

	Reviewer 1	Reviewer 2	Reviewer 1	Reviewer 2

Initial data gathering by physician about acute problems	163 (91.6)	151 (84.8)	12 (6.7)	25 (14.0)

Physician integration of information and development of appropriate diagnoses	147 (82.6)	159 (89.3)	10 (5.6)	41 (23.0)

Physician initial treatment plan and orders	117 (65.7)	126 (70.8)	10 (5.6)	26 (14.6)

Physician plan for disposition and follow-up	146 (82.0)	167 (93.8)	10 (5.6)	64 (36.0)

Overall quality of care	136 (76.4)	141 (79.2)	10 (5.6)	22 (12.4)


Category #	Job title	# of participantsinterviewed

1	Laboratory Manager	3

2	Transfusion Safety Officer	2

3	Lab Technologist (Blood Bank)	9

4	Physicians - Blood Bank	4

5	Physicians - who use blood products	7

6	Hospital Administration	4

7	Hospital PR	1

8	Hospital Risk Management	2

9	Blood Suppliers (CBS, Hema-Quebec)	9

11	MoH (Provincial)	2

13	Recipients of blood products	2

11	Total	45


Description	Selected study

Critical endpoint	Acute irritation of the eyes and upper airways

	A few (4 out of 27) individuals reacted with additional cough and slight airway obstruction

Source	The Health Council of the Netherlands (2007) (Wieslander et al., 2001)

Species	Healthy human subjects (27)

Exposure regimen	Propylene glycol in aviation emergency training. Exposure to artificial mist generator in short-term inhalation exposure (~1 min)

Concentrations tested (mg/m3)	0, 176-851

Duration of exposure	Average rating on 10 questions before and after 1 min propylene glycol exposure every 30 min for 4 hours

NOAEL (mg/m3)	-

If no NOAEL, then value for LOAEL	Min = 176

	Max = 851

	Mean = 309

Calv;max (mg/m3)	430-603

Source of Calv;max (mg/m3)	1 puff (50 mL [5], 70 mL [6])

MOE1-puff shisha-pen/100% transfer rate	Min range = 0.3-0.4 (~2.5-3x higher than in human study)

	Max range = 1.4-2

	Mean range = 0.5-0.7 (~1.4-2x higher than in human study)


Variables	n (%)

Marital status	single	47 (13.6)

married	259 (75.1)

divorced	37 (10.7)

widow	2 (0.6)

Education	primary	1 (0.3)

vocational	7 (2.0)

secondary	78 (22.6)

higher	259 (75.1)

Place of residence	village	41 (11.9)

town of up to 10,000 residents	10 (2.9)

town of up to 100,000 residents	44 (12.7)

city with more than 100,000 residents	250 (72.5)

Employment status	employed	331 (96.5)

unemployed	12 (3.5)

Number of pregnancies	0	42 (12.2)

1	92 (26.8)

>1	210 (61.0)


Outcomes	Standard Therapy (n = 32)	Acupuncture (n = 34)	p*

Primary outcomes

VAS

Mean VAS score at baseline (SD)	8.02 (1.69)	7.81 (1.48)	0.6

Mean VAS score after therapy (SD)	3.89 (2.38)	2.96 (1.84)	0.08

Mean change in VAS score (SD)	4.12 (2.29)	4.85 (1.87)	0.12

Response rate (>=2 VAS units decrease), %	81.6	89.2	0.8

Secondary outcomes

McGill score

Mean McGill score at baseline (SD)	2.32 (1.05)	2.38 (1.12)	0.8

Mean McGill score after therapy (SD)	0.99 (0.69)	0.99 (0.73)	0.9

Mean change in McGill score (SD)	1.32 (0.85)	1.33 (0.88)	0.9

Post-herpetic neuralgia at 3 months, %	48.4	46.8	0.9

Post-herpetic neuralgia at 6 months, %	33.3	29.0	0.7

Post-herpetic neuralgia at 12 months, %	10.3	3.6	0.3

Mean AUC during follow-up (SD)	199(136)	173(141)	0.5


Predictor	Odds Ratio	95% Confidence Interval

Age	0.97	0.95	1.00*

Education	0.93	0.87	1.01

Services	0.98	0.84	1.14

Partner support	0.88	0.80	0.97**

Mother support	0.95	0.89	1.01

Father support	0.95	0.88	1.02

Weeks pregnant	1.01	0.99	1.02

Single vs. married/living together	0.93	0.68	1.28

Informal housing vs. formal	1.04	0.72	1.49

Unemployed vs. employed	1.09	0.76	1.56

HH income < R2000 p/m	1.52	1.15	2.01**

No income baby father	1.20	0.78	1.83

Tobacco use	1.33	0.67	2.65

Alcohol use	1.22	0.89	1.66

Relationship violence	1.49	1.13	1.96**


Surgical procedure	Vault prolapse	POP-Q III	POP-Q IV

 Sacrospinous fixation 	 4 	 5 	 23

 Anterior colporrhaphy 	 2 	 5 	 23

 Enterocele repair 	 3 	 1 	 20

 Bladder neck suspension 	 1 	 - 	 4


Class	TP rate	FP rate	Precision	Recall	f-measure	ROC area	Accuracy

Migraine	1	1	0.716	1	0.835	0.5	100.00%

Cluster	0	0	0	0	0	0.5	0.00%

Tension	0	0	0	0	0	0.5	0.00%

No headache	0	0	0	0	0	0.5	0.00%

Weighted avg	0.716	0.716	0.513	0.716	0.598	0.5	71.60%


 	Number of respondents	Percentage (95% CI)

Equipment cost	177	89.4% (85.7-93.1)

Training costs	146	73.7% (68.4-79)

Challenges in training	106	53.5% (47.5-59.5)

Transport times	95	48% (42-54)

Concerns about delaying time to definitive care	90	45.5% (39.5-51.5)

Ultrasound is beyond the scope of practice of providers	76	38.4% (32.6-44.2)

Lack of evidence	76	38.4% (32.6-44.2)

Approval by EMS administration	25	12.6% (8.6-16.6)

Buy-in by other EMS medical directors	21	10.6% (6.9-14.3)

Regulatory factors	29	14.6% (10.4-18.8)


Average hours per month	Programs Reported Resident UseNo. (%)

< 1 h	17 (38)

1–2 h	14 (31)

3–5 h	2 (4)

6–10 h	1 (2)

> 10 h	1 (2)

No response	10 (22)


Outcomes	Instrument	t0	t1	t2	t3	t4	t5	t6

Primary endpoint

Overall 2-year survival	Medical log (ongoing assessment)

Secondary endpoints

2-year non-relapse mortality, median (disease-free) survival	Medical log (ongoing assessment)

Quality of life	EORTC QLQ30 / HDC-29 module	X	X	X	X	X	X	X

Fatigue	Multidimensional Fatigue Inventory (MFI)	X	X	X	X	X	X	X

Muscle strength	Isometric and isokinetic strength of representative muscle groups for upper and lower extremity measured at the IsoMed2000®	X			X		X	X

Hand-Held-Dynamometer (isometric)	X	X	X	X	X	X	X

Cardiorespiratory fitness	CPET (VO2peak)	X			X		X	X

	6-min Walk Test	X	X	X	X	X	X	X

Body composition	bioelectrical impedance analysis, weight, height	X	X	X	X	X	X	X

Physical Activity	Accelerometry	X		X	X	X	X	X

Depression	CES-D	X	X	X	X	X	X	X

Distress	NCCN-Distress	X	X	X	X	X	X	X

Locus of control	KKG (German)	X	X	X	X	X	X	X

Cognitive function	Trail-making-test	X	X	X	X	X	X	X

Common side-effects	VAS, every week, later every 3 weeks

Biomarker	Various methods (ELISA)	X	X	X	X	X	X	X

Oxidative stress marker	Analysed in urine samples	X	X	X	X	X	X	X

Others

Socio-demographic factors	Recording of date of birth, education, occupation, familial situation, smoking, alcohol consumption	X					X	X

Medical history	Recording of pre-existing diseases, therapies	X

Treatment data	Conditioning, complications		X

Karnofsky Performance Score	Physician rating	X	X	X	X	X	X	X

Medication (immunosuppression, corticosteroids, analgesics)	Recorded at each visit/phone call on a medication log form	X	X	X	X	X	X	X

Physical activity history	Physical activity in adolescence, pre-diagnosis, during, and after intervention is recorded, including walking, cycling, and sports activities	X			X		X	X


Individual components of global assessment of inflammation	Patients with grade 0, n (%)

 	Difluprednate 0.05% (n=39)	Prednisolone acetate 1% (n=40)

Anterior chamber cell	30 (78.9)	31 (77.5)

Anterior chamber flare	29 (74.4)	28 (70.0)

Corneal clarity	37 (94.9)	36 (90.0)

Conjunctival injection	35 (89.7)	37 (92.5)

Ciliary/limbal injection	39 (100.0)	40 (100.0)

Chemosis	39 (100.0)	39 (97.5)

Hypopyon	39 (100.0)	40 (100.0)

Vitritis	39 (100.0)	39 (97.5)

Wound integrity	39 (100.0)	40 (100.0)

Photophobia	38 (97.4)	38 (95.0)

Lacrimation	39 (100.0)	38 (95.0)


Ingredients	% of DM

Mix Silage	39.00

Mix Hay	5.00

Barley	18.09

Oats	15.12

Rape Seed Cake	6.48

Rape Seed Meal	2.16

Brewers Grain	2.16

Soybean Meal	3.78

Dried Sugar Beet Pulp	5.40

Wheat Bran	0.81

Mineral Mix1	2.00

Nutrients analysis	% of DM

DM (%)	52.50

CP	17.20

NDF	35.94

Ether extract	3.72

Ash	9.01

Ca	0.89

P	0.46

NEL MJ/kg of DM	6.95


Main nutrients 	Rice porridge	Rice cereal *	Hard-boiled egg yolk

Energy, including dietary fibre (kJ)	158	1537	1450

Protein (g)	0.7	6.8	16.1

Fat (g)	0.1	1.1	31.7

Calcium (mg)	2	6	115

Iodine (ug)	0.8	3.7	127.7

Iron (mg)	0.08	15.5	4.8

Zinc (mg)	0.12	7.8	2.7

Riboflavin (B2) (mg)	0.002	1.9	0.42

Pyridoxine (B6) (mg)	0.01	0	0.33

Vitamin C (mg)	0	33	0

Folate, natural (μg)	1	70	177


Variable	Laser	Steel	Total	p-value

Age	 	 	 	0.548

Mean	65.2	67.4	66.3

Range	-	-	34-87

SD	11.5	12.7	12.0

Gender	 	 	 	1.0

Male	20	19	39

Female	3	3	6

Diagnosis	 	 	 	0.463

a) Premalignant

Moderate dysplasia	0	2	2

Severe dysplasia/CIS	6	3	9

b) Invasive SCC

Well differentiated	2	2	4

Moderately differentiated	12	14	26

Poorly differentiated	3	1	4


Cluster description	Codon	Size	Example organism (locus)

Selenocysteine

Formate dehydrogenase α subunit	TGA	45	Escherichia coli (b1474)

Selenide water dikinase	TGA	12	Haemophilus influenzae (HI0200m)

Glycine reductase complex selenoprotein A	TGA	6	Treponema denticola (TDE0745)

Glycine reductase complex selenoprotein B	TGA	6	Treponema denticola (TDE0078)

Heterodisulfide reductase subunit A	TGA	6	Methanococcus jannaschii (MJ1190m)

Coenzyme F420-reducing hydrogenase δ subunit	TGA	5	Methanococcus jannaschii (MJ1190a)

Formylmethanofuran dehydrogenase subunit B	TGA	4	Methanococcus jannaschii (MJ1194m)

Glutaredoxin-like	TGA	3	Carboxydothermus hydrogenoformans (CHY_0740)

Thioredoxin	TGA	3	Geobacter sulfurreducens (GSU3446)

Coenzyme F420-reducing hydrogenase α subunit	TGA	3	Methanococcus jannaschii (MJ0029)

HesB family	TGA	3	Desulfovibrio vulgaris (DVU_1382)

HesB family	TGA	2	Methanococcus maripaludis (MMP0252 + upstream)

Fe-S oxidoreductase	TGA	2	Desulfotalea psychrophila (DP1009)

DsbA-like	TGA	2	Desulfovibrio desulfuricans (Dde_1263 + upstream)

Periplasmic [NiFeSe] hydrogenase large subunit	TGA	2	Desulfovibrio vulgaris (DVU_1918)

Pyrrolysine

Monomethylamine methyltransferase	TAG	7	Methanosarcina acetivorans (MA0144)

Dimethylamine methyltransferase	TAG	7	Methanosarcina acetivorans (MA0532)

Trimethylamine methyltransferase	TAG	6	Methanosarcina acetivorans (MA0528)

Transcriptional regulator, TetR family	TAG	2	Methanosarcina acetivorans (MA2902)

Unknown

Cytochrome c family protein	TGA	2	Geobacter sulfurreducens (GSU2937 + GSU2936)

Hypothetical protein	TAG	2	Geobacter sulfurreducens (GSU2293 + downstream)


	Intention-to-treat analysis	Per protocol analysis

	1 Hz (n = 22)	25 Hz (n = 24)	Group comparison	1 Hz (n = 17)	25 Hz (n = 23)	Group comparison

Treatment period (days)	77.9 ± 25.8	85.7 ± 11.4	p = 0.22	89.0 ± 8.4	87.5 ± 7.5	p = 0.67

Average number of stimulated hours per day	3.42 ± 0.59	3.44 ± 0.61	p = 0.69	3.34 ± 0.62	3.44 ± 0.62	p = 0.51


Variables		Patients	KRAS	NRAS	BRAF

		n	%	n	n	n

Age	≤ 55	14	64	4	1	3

	> 55	8	44	2	0	1

Gender	male	16	73	2	1	4

	female	6	27	4	0	0

Histology	ADC with SRC	3	14	0	0	1

	ADC without SRC	19	86	6	1	3

Calcification	present	3	14	1	0	0

	absent	19	86	5	1	4

Sheldon Stage	I-II	0	0	0	0	0

	IIIA	10	45	2	1	2

	IIIB	7	32	4	0	1

	IIIC	1	5	0	0	0

	IVA	2	9	0	0	0

	IVB	2	9	0	0	1

	IVC	0	0	0	0	0

Mayo stage	I	4	19	1	0	0

	II	10	48	3	1	3

	III	5	24	2	0	0

	IV	2	9	0	0	1

	missing	1

LN or distant meta at diagn.	N0/M0	18	82	6	1	3

	N + / M+	4	18	0	0	1

Initial surgical treatment	partial CE	15	68	5	0	3

	radical CE	5	23	1	0	0

	TURB	2	9	0	1	1

Umbilectomy	yes	11	50	4	0	2

	no	11	50	2	1	2

LND	yes	13	59	3	0	2

	no	9	41	3	1	2

Chemotherapy	yes	6	27	1	1	2

	no	16	73	5	0	2

Progression	local recurrence	2	9	1	1	1

	distant met	2	9	1	0	0

	both	5	23	2	0	1

	no progression	13	59	3	0	2


	Alcohol intake (g/day)

	0	0.1–5	5.1–15	>15

No. of participans	10,153	22,249	11,734	1,097

Age at enrollment (mean)	39.8	39.7	40.5	41.4

Educational attainment >11 years, (%)	46.3	56.3	61.4	61.7

History of breast cancer in mother and/or sister (%)	4.2	4.2	5.3	5.9

Smoking habits (%)

 Never	50.5	43.0	32.0	18.1

 Former	28.2	35.3	40.7	40.7

 Current	21.3	21.7	27.3	41.2

Age at menarche (mean)	12.9	13.0	13.0	13.1

Women with more than 3 children (%)	32.5	27.2	24.0	23.4

Age at first child birth among parous women (mean)	23.5	24.0	24.1	23.8

Total duration of breast feeding (months)	30.9	30.8	30.2	30.3

Ever oral contraceptive use (%)	75.1	85.0	88.2	89.7

Post-menopause (%)	4.4	3.8	4.3	3.7

Body mass index (>25 kg/m2, %)	31.9	24.1	21.1	24.6


 	Location	Group	IHC grade#	P value*

 	Stroma	Cancer nest	−	+	++	+++	++++

α-SMA	Positive$	ND	Chronic nasopharyngitis (21)	11	7	2	1	0	0.000

NPC (18)	0	4	0	7	7

CD133	Positive	ND	Chronic nasopharyngitis (10)	9	1	0	0	0	0.006

NPC (30)	8	9	9	4	0

VEGFR-2	Positive	ND	Chronic nasopharyngitis (8)	7	1	0	0	0	0.04

NPC (10)	2	5	1	2	0

CD34	Positive	ND	Chronic nasopharyngitis (14)	0	8	6	0	0	0.000

NPC (24)	0	0	3	7	14

CXCR4	Positive	Positive	Chronic nasopharyngitis (6)	0	3	1	2	0	0.041

NPC (11)	0	0	2	4	5

VEGF-A	Positive	Positive	Chronic nasopharyngitis (10)	0	1	5	4	0	0.015

NPC (19)	0	0	2	9	8

SDF-1	ND	Positive	Chronic nasopharyngitis (22)	5	9	5	2	1	0.008

NPC (20)	3	0	7	5	5


Specific primer	Primer sequences (5′–3′)

N type DlRans	Forward: AAGGACAGCTCTCATGGCTTTGC

Reverse: TGCCTCCATCACCGACGATGAC

D type DlRans	Forward: TAGTGATCGTCGGCGATGGTGG

Reverse: TGCAGTGTCCCAGCAATAGAAGCG

Fe-SOD	Forward: GGTCAGATGGTGAAGCCGTAGAG

Reverse: GTCTATGCCACCGATACAACAAACCC

EF-1a	Forward: GATGATTCCCACCAAGCCCAT

Reverse: GGGTCCTTCTTCTCAACACTCT


Group	Swell degree (mg)	Inhibition rate (%)

Fenli	5.13 ± 0.68	69.15

DE MDTS	5.86 ± 1.76	64.76

Control	16.63 ± 1.57


Workflow	Sequential	Parallel

Preprocess (clipOverlap)	2.82	2.91

SNV: mutationSeq	5.68	5.99

SNV: Strelka	2.60	4.49

CNV: Titan	29.34	36.31

CNV: Sequenza	8.24	9.40


Gene Name	Primers

Rbcl (ribulose-1,5-bisphosphate carboxylase/oxygenase: Genbank-KR914695.1)	Rbcl1: ACGAATGTTTACGCGGTGGTCT

Rbcl2: GGTACACCCAACTCCTTAGCA

CrtZ (carotenoid hydroxylase: Genbank-KP866868.1)	CrtZ1: ATCTTCGCCACCTACCTGAG

CrtZ2: CGGGCAGTCCATTGATGATT

LcyB (lycopene beta cyclase: Genbank-AY182008.1)	LcyB1: CTTTGACCCAGCACGACTTG

LcyB2: TTAGGAACTTCTCGCCCTCT

CrtISO (carotenoid isomerase: Genbank-KP780062.1)	CrtISO1: GCACCACTAACCTCATCACA

CrtISO2: CCTTCCAGCAGTCGTCATAA

ZEP (zeaxanthin epoxidase: Genbank-KP780061.1)	ZEP1: TACCTCAACCCTGCTCCTGA

ZEP2: TTCGCCCTTCTCAAGCCTGT


Test	Method

Blood testsAs listed in table 1, plus:

 Collagen C-telopeptide (CTX)Osteocalcin (OC)	Roche Elecsys beta cross-lapsRoche Elecsys 2010Canterbury District Health Board Laboratory

Weight at baseline and 6 months	Tanita electronic scales


	Rule role	Rule example	Location term

Ex. 1	Type disambiguation	IF dead, decaying in term THEN type =Env	dead animal (Host) becomes dead animal (Env)

Ex. 2	Boundary extension	IF nationality before term (Env) THEN include nationality	oil field (Env) becomes German oil field (Env)

Ex. 3	Boundary reduction	IF irrelevant modifier in term THEN delete modifier	infected rodent (Host) becomes rodent (Host)


	Clients & informal caregivers (n = 28)	Health care providers (n = 20)

Urban (n = 16)	Male	4	0

Female	8	4

Rural (n = 32)	Male	1	1

Female	15	15


	Median duration of stay (days) for SARI cases	Median duration in ICU (days) for SARI cases with ICU treatment	Median duration of ventilation (hours) for ventilated SARI cases

Case definition	< 5	5–14	15–34	35–59	60+	all	< 5	5–14	15–34	35–59	60+	all	< 5	5–14	15–34	35–59	60+	all

BCD	4	4	4	6	8	6	3	4	3	3	3	3	100	140.5	78	74	61	69

SCD	4	4	5	8	10	8	3	4	4	5	4	4	118	143	128.5	142	95	104

TCD	4	4	3	4	5	4	2	3	1	1	1	2	44	117	47	41.5	32	37


Gene id	ContiguousE. histolytica DNA region ID	Length (bp)	Location of SNP(s) (bp)

EHI_080100	DS571720	5179	2725-2730

EHI_065250	DS571302	38246	10296-10318


Antimicrobial agents	MIC range	MIC50	MIC90	Resistance (%)	Susceptible (%)

Cefoperazone–sulbactam	16–256	64	128	85.4	4.2

Ampicillin–sulbactam	16–128	64	128	93.8	0

Piperacillin–tazobactam	128 to >256	>256	>256	100	0

Ceftazidime	32–64	64	64	100	0

Cefepime	32–64	64	64	100	0

Imipenem	1–32	32	32	95.8	2.1

Meropenem	2–32	32	32	95.8	2.1

Amikacin	8 to >128	>128	>128	83.3	16.7

Gentamicin	2–64	64	64	95.8	4.2

Ciprofloxacin	16	16	16	100	0

Levofloxacin	4–32	8	32	91.7	0

Trimethoprim–sulfamethoxazole	1–16	16	16	97.9	2.1

Colistin	1–32	1	2	4.2	93.8

Tigecycline	0.25–2	0.5	1	0	100


Group	Sequence	Repeat times

A1	DYDRYSSALIAA	5

A3	YWTPGYTPSQTE	1

A7	NNSRDTALRWFV	1

A13	GQPKTFLSVSEL	5


No.	Primer’s name	Forward sequence	Reverse sequence	Annealing time and temperature

1	otud4	CCACCTCCTGCAGAACAAAAG	GGGTCTTGGTAAAGGCTCATT	15 s/60 °C

2	cx43 (gja1)	TGCTGCGAACCTACATCATC	CGATGACGTTCAAGGCAAGA	15 s/60 °C

3	sod2	GTCACCGAGGAGAAGTACCA	CTGGTTAGGACAGGCAACAA	15 s/60 °C

4	sod1	GATTCCACGTCCACGAGTTT	CCCGAGAGTGAGATCACAGA	15 s/60 °C

5	tgfb2	AGTACTACGCCAAGGAGGTT	TAGGCGGGATGGCATTTTCC	15 s/60 °C

6	myf5	GGAGACGCCTGAAGAAAGTC	CCGGCAGGCTGTAGTAATTC	15 s/60 °C

7	bdnf	CCCCATGAAAGAAGCAAACG	TACAAGTCCGCGTCCTTACT	15 s/60 °C

8	gapdh	GTTTGTGATGGGCGTGAACC	GTCTTCTGGGTGGCAGTGAT	15 s/60 °C


Organism	Inpatient	Outpatient	Pediatrics	Missing	Total

Streptococcus species	162	16	19	9	206

Neisseria species	94	11	2	0	107

Haemophilus species	47	2	9	1	59

Staphylococcus aureus	34	1	1	0	36

Escherichia coli	13	7	1	1	22

Other Gram negative	20	2	0	0	22

Other Gram positive	12	0	1	0	13

Enterococcus species	8	0	1	0	9

Acinetobacter species	6	0	2	0	8

ESBL’s Klebsiella pneumoniae	6	1	0	0	7

Klebsiella	7	0	0	0	7

Pseudomonas species	0	0	7	0	7

Total	409 (81.3%)	40 (8.0%)	43 (8.5%)	11 (2.2%)	503 (100%)


 	Administration	Clearance	Side effects

GLP-1R agonist	Subctaneous	 	Weight loss	Gastrointestinal tract (GIT)

Exenatide	Twice a day, once a week	Renal	+	++/±*

Liraglutide	Once a day	Extrarenal	+	+

DPP-4 inhibitor	Oral	 	→	→

Sitagliptin	Once a day	Renal	→	→

Vildagliptin	Twice a day	Renal	→	→

Saxagliptin	Once a day	Renal	→	→

Linagliptin	Once a day	Extrarenal	→	→

Anagliptin	Twice a day	Renal	→	→

Teneligliptin	Once a day	Extrarenal > renal	→	→

Alogliptin	Once a day	Renal	→	→


MIGS ID	Property	Term	Evidence codea

	Classification	Domain Bacteria	TAS [37]

		Phylum Bacteroidaeota	TAS [3]

		Class Flavobacteriia	TAS [38]

		Order Flavobacteriales	TAS [39]

		Family Flavobacteriaceae	TAS [40]

		Genus Elizabethkingia	TAS [2]

		Species Elizabethkingia meningoseptica	TAS [2]

		Strain Em3	TAS [2]

	Gram stain	Negative	IDA

	Cell shape	Rod	IDA

	Motility	Non motile	IDA

	Sporulation	Non-spore-forming	NAS

	Temperature range	4–40 °C	IDA

	Optimum temperature	37 °C	IDA

	pH range; Optimum	4–10; 8	IDA

	Carbon source	Heterotroph	IDA

	Energy source	Varied; including glucose and mannitol	IDA

MIGS-6	Habitat	Human	NAS

MIGS-6.3	Salinity	Not determined

MIGS-22	Oxygen requirement	Aerobic	NAS

MIGS-15	Biotic relationship	Free-living	NAS

MIGS-14	Pathogenicity	Pathogen	NAS

MIGS-4	Geographic location	Michigan, USA	NAS

MIGS-5	Sample collection time	February, 6, 2016	NAS

MIGS-4.1	Latitude	42° 43′ 57′′ N	NAS

MIGS-4.2	Longitude	84° 33′ 20′′ W	NAS

MIGS-4.4	Altitude	Not reported	NAS


Included trials	Selective head cooling	Whole body cooling

	Gunn 1998	Gluckman 2005	Shankaran 2002	Shankaran 2005	Eicher 2005

Design	RCT	RCTMulticenter	RCTMulticenter	RCTMulticenter	RCTMulticenter

Number of participants	26	234	19	208	65

Gestation	≥ 37 wks	≥ 37 wks	≥ 36 wks	≥ 37 wks	≥ 35 wks

Inclusion criteria (details see Table 2)	Asphyxia and moderate to severe HIE	Asphyxia and moderate to severe HIE	Asphyxia and moderate to severe HIE	Asphyxia and moderate to severe HIE	Asphyxia and HIE

Target temperature treatment group (°C)	34.5–35.5 (n = 6)34.0–35.0 (n = 7)Not analyzed:36.0–36.5 (n = 6)35.5–35.9 (n = 6)	34.0–35.0	34.5	33.5	32.5–33.5

Target temperature control group (°C)	36.8–37.2	36.5–37.5	36.5	36.5–37.0	36.5–37.5

Site of temperature probe	Rectal	Rectal	Esophageal	Esophageal	Rectal

Average age at start of cooling (min)	294	330	318	302	120

Duration of cooling (h)	48–72	72	72	72	48

Cooling device	Servo-controlled cooling cap	Servo-controlled cooling cap	Two servo-controlled cooling blankets	Two servo-controlled cooling blankets	Ice bags followed by one servo-controlled cooling blanket

Primary outcome	Adverse events	Composite of death/severe disability	Adverse events	Composite of death/moderate or severe disability	Adverse events

Latest follow-up (months)	18	18	Follow-up not reported	18–22	12

Follow-up tools	Bayley II	Bayley IIGMF	-	Bayley IIGMF	Bayley IIVineland


Candidate Biomarker	Comparison	Difference	Lower CI	Upper CI	Q-value

CEA	Malignant/Non-malignant	1.97	1.08	2.85	0

CEA	Malignant/Healthy	2.11	1.02	3.19	0

IL.8	Malignant/Healthy	1.22	0.14	2.31	0

Prolactin	Non-malignant/Healthy	1.1	0.02	2.19	0.04


Health professional/service	Communications sent out	Communications received

6	Oncologist	0	1

7	Psychologist	0	1

9	Neurosurgeon	5	1

16	Primary nurse, Oncology	0	0

23	Family Physician	0	1

30	Pediatrician/Palliative Care	0	0

36	Oncologist	0	1

38	Oncologist	0	2

42	Pediatrician/Palliative Care	0	1

44	Neurosurgeon	0	3

47	Neurosurgeon	3	0

78	Canuck Place	3	0

	Mean	0.92	0.92


 	Free attention (FA)	 	Attention to the right (AR)	 	Attention to the left (AL)

P	G	P	G	P	G

Mean	1.04	0.67	 	2.18	2.63	 	2.31	1.71

S.D	1.22	0.98	 	1.70	2.88	 	2.06	2.21

Mann-Whitney Test (P X G)	0.288	 	 	1.00	 	 	0.396


	Magnetic Detection	Microbiological Tests

Anti-Streptococcus agalactiae	Anti-GB Streptococci

Mastitic Milk Isolates		Correctly Identified		Correctly Identified		Correctly Identified

	n	n	%	MI 1	n	%	MI	n	%	MI

S. aureus	1	0	0.0	0	1	100.0	0	0	0.0	1

S. agalactiae	13	7	70.0	3	2	25.0	6	13	100.0	0

S. uberis	11	3	33.3	6	5	62.5	3	8	72.7	3

Streptococcus spp.	4	0	0.0	3	2	50.0	2	1	25.0	3

Staphylococcus spp.	2	0	0.0	0	1	50.0	1	2	100.0	0

Enterococcus spp.	7	3	75.0	1	1	33.3	2	0	0.0	7

Escherichia coli	3	0	0.0	1	1	50.0	1	3	100.0	0

Yeasts	3	0	0.0	2	1	100.0	0	2	66.7	1

Prototheca	2	0	0.0	2	1	50.0	1	2	100.0	0

TOTAL	46	13	41.9	18	15	48.4	16	31	67.4	15


	NPWT (n = 19)	Usual care (n = 21)	Total (n = 40)

Age (years)*	58·8(15·1)	56·9(13·9)	57·8(14·4)

Sex ratio (M : F)	11 : 8	11 : 10	22 : 18

BMI (kg/m2)*	29·2(5·6)	29·0(6·0)	29·1(5·7)

Diabetes	12	12	24

Peripheral arterial disease	7	7	14

Tobacco use

None	13	10	23

Ex‐smoker	1	6	7

Current (≤ 1 pack/day)	2	4	6

Current (> 1 pack/day)	3	1	4

Previous history of SWHSI

Yes	5	5	10

No	11	15	26

Unknown	3	1	4

Wound area (cm2)†	18·2 (0·2–122·5)	20·4 (2·3–93·2)	19·3 (0·2–122·5)

< 28	10	11	21

≥ 28	9	10	19

Wound duration (days)†	7 (0–27)	12 (1–142)	7 (0–142)

Wound infected

Yes	5	8	13

No	14	13	27

Wound location

Foot	11	13	24

Abdomen	3	3	6

Leg	3	1	4

Breast	1	1	2

Groin	0	2	2

Buttocks	0	1	1

Perianal area	1	0	1

Type of surgery‡

Elective	12	18	30

Emergency	6	3	9

Contamination level of surgery

Clean	6	2	8

Clean‐contaminated	9	12	21

Contaminated	4	7	11


Model description

	Y	No. of variables	No. of observations	Degrees of freedom

	SMR	3	2306	2303

Model fit

	R2		Log likelihood	AIC

	0.2238		-235.357	476.713

Model estimation

	Variable	Coefficient	Std. Error	t-Statistic	P

	ρ	0.4962	0.0231	21.496	0.0000

	CONSTANT	0.3605	0.0304	11.859	0.0000

	AOD	0.5367	0.1522	3.527	0.0004

Diagnostic tests

	Tests	DF	Value	p

Heteroskedasticity	Breusch-Pagan	1	0.156	0.6933

Spatial dependence	Likelihood Ratio	1	434.813	0.2745


Cancer types	Key message(s)	Ref.

Breast cancer	Dephosphorylation of FOXO3a induced by Aplysin suppresses tumor growth by inhibiting cell proliferation and promoting apoptosis in cancer cells.	[89]

Prostate cancer	Deregulation of FOXO3a promotes prostate cancer progression in TRAMP mice.	[90]

Acute myeloid leukemia	Dephosphorylation of FOXO3a induced by hypomethylating agents promote apoptosis by upregulation of BIM and PUMA expression.	[91]

Colon cancer	Activation of FOXO3a by aldose reductase induces human colon cancer cell apoptosis by upregulating both DR5 and DR4.	[92]

Lung cancer	Deregulation of FOXO3a promotes DNMT3B overexpression leading to tumor growth in lung cancer.	[93]

Glioma	A high expression of FOXO3a is associated with glioblastoma progression and FOXO3a level independently indicates poor prognosis in Glioma patients.	[94]

Thyroid cancer	Nuclear FOXO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1 and accelerates proliferation of human ATC cells.	[95]

Lung adenocarcinoma	FOXO3a gene inactivation occurs frequently in carcinogen-induced lung adenocarcinoma.	[96]

Oral squamous cell carcinoma	Constitutively active form of FOXO3a induces significant G1-phase arrest and apoptosis in OSCC cells	[97]

Neck cancer	Tumor patients with low FOXO3a expression have a poor prognosis compared with patients with high FOXO3a.	[98]

Urothelial cancer	FOXO3a suppresses invasiveness of urothelial cancer through regulation of Twist1, YB-1 and E-cadherin.	[99]

Osteosarcoma	Activation of FOXO3a by ionizing radiation induces cell apoptosis in osteosarcoma.	[100]

Bladder cancer	Upregulation of FOXO3a by Nkx2.8 suppresses bladder cancer proliferation.

Gastric cancer	FOXO3a cooperates with RUNX3 to induce apoptosis by activating Bim in gastric cancer cells.	[60, 101]

Neuroblastoma	Inactivation of FOXO3a by AKT is essential for neuroblastoma cell survival.	[102]

Ovarian cancer	Inhibition of FOXO3a phosphorylation by BrMC upregulates Bim expression and leads to apoptosis in ovarian cancer cells.	[103]


Rate of failure in control group (%)	Rate of failure in the intervention group (%)

	10	15	25

	80% power	90% power	80% power	90% power	80% power	90% power

25	100	133

30	62	82	121	161

35	43	57	73	97	329	440


Variables	Renal cell carcinoma (n = 76)

Age (mean, years)	61.3 ± 13.5

Sex

Male	45

Female	31

Tumor type

Clear cell	59

Papillary	11

Chromophobe	4

Sarcomatoid carcinoma	2

Pathologic grade

Grade 1 and 2	57

Grade 3 and 4	19

Tumor stage

Stage 1 and 2	52

Stage 3 and 4	24


	2003	2004	2005	2006	2007	Total

Number of complicated induced abortions 	23	13	11	18	46	111

Number of admission into gynaecological ward	757	716	471	785	818	3547

Number of live births	1543	1479	1512	1756	2101	8391

Percentage of gynaecological admission 	3.0	1.8	2.3	2.3	5.6	3.1%

Ratio of complicated induced abortion per 1000 live births 	14.9	8.8	7.3	10.3	21.9	13.2/1000


Year	Journal	Title of the paper	First author; volume number; page numbers

2013	Public health action	The burden and outcomes of childhood tuberculosis in Cotonou, Benina	Ade S; vol 314; no 1; 15–19

2013	Public health action	MDR-TB treatment needs in patients previously treated for TB in Cotonou, Beninb	Ade S; vol 3; no 2; 160–165

2013	Transactions of the royal society of tropical medicine and hygiene	National profile and treatment outcomes of adult smear-negative pulmonary TB patients in Beninb	Ade S; 10.1093/trstmh/trt092

2014	PLoS One	National profile and treatment outcomes of patients with extrapulmonary tuberculosis in Benina	Ade S; vol 9; no 4; e95603

2015	Public health action	Low prevalence of diabetes mellitus in patients with tuberculosis in Cotonou, Beninb	Ade S; vol 5; no 2; 147–149

2016	BMC health services research	Follow-up and tracing of tuberculosis patients who fail to attend their scheduled appointments in Cotonou, Benin: a retrospective cohort studya	Ade S; vol 5; no 2; 7 pages; 10.1186/s12913-015-1219-z

2016	Tuberculosis research and treatment	Characteristics and treatment outcomes of retreatment tuberculosis patients in Beninb	Ade S; vol 2016, Article ID 1468631, 7 pages http://dx.doi.org/10.1155/2016/1468631

2016	Tuberculosis research and treatment	Tuberculosis case finding in Benin, 2000–2014 and beyond: a retrospective cohort and Time Series Studyb	Ade S; volume 2016, Article ID 3205843, 9 pages http://dx.doi.org/10.1155/2016/3205843


Treatment [Reference]	Annual exacerbation rate	Comparator	Annual exacerbation rate	Reduction in exacerbations	Exacerbation endpoint	Patient population

Exacerbation entry criteria (No./year)	FEV1 % predicted

ICS

 FP [131]	0.93	Placebo	0.73	NS	Primary	NA	<90 % (post-BD)

 FP [13]	0.93	Placebo	1.13	18 %	Secondary (moderate or severe)	NA	<60 % (pre-BD)

 FP [65]	1.05	Placebo	1.30	19 %	Secondary (any)	≥1	25–70 % (pre-BD)

 FP [132]	0.99	Placebo	1.32	25 %	Secondary (any)	NA	<85 % (post-BD)

LABA/ICS

 SFC [133]	0.44	Salmeterol	0.48	NS	Primary (severe)	≥1 (last 14 days)	<70 % (pre-BD)

 SFC [134]	1.10	Salmeterol	1.59	30.4 %	Primary (moderate or severe)	≥1	<50 %

 SFC [13]	0.85	PlaceboSalmeterolFP	1.130.970.93	25 %12 %9 %	Secondary (moderate or severe)	NA	<60 % (pre-BD)

 SFC [65]	0.97	Placebo	1.30	25 %	Secondary (moderate)	≥1	25–70 % (pre-BD)

 SFC [135]	1.06	Salmeterol	1.53	30.5 %	Primary	≥1	<50 %

 SFC [61, 136]	1.28	Tiotropium	1.32	NS	Primary (moderate or severe)	NA	<50 % (post-BD)

 SFC [137]	0.92	Salmeterol	1.4	35 %	Primary (moderate or severe)	≥2	<50 % (post-BD)

 Bud/Form [80]	1.38	PlaceboFormeterolBudesonide	1.801.851.60	23.6 %NSNS	Primary (all)	≥1	<50 % (pre-BD)

 Bud/Form [81]	1.42	PlaceboFormoterolBudesonide	1.871.841.59	24 %23 %NS	Primary (severe)	≥1	<50 %

 Bud/Form [138]	0.70 (320/9 μg)0.79 (160/9 μg)	Formoterol	1.07	34.6 %25.9 %	Primary (moderate or severe)	≥1	≤50 % (pre-BD)

 Bud/Form [139]	NR	Formoterol	NR	36 %	Secondary (any)	≥1	≤50 % (pre-BD)

 FF/VI [79]	0.81	Vilanterol	1.11	30 %(Pooled data)	Primary (moderate or severe)	≥1	<70 % (post-BD)

 BDP/FOR [140]	0.80	Formoterol	1.12	28 %	Primary (moderate or severe)	≥1	<50 %

 BDP/FOR [141]	0.41	Bud/Form Formoterol	0.420.43	NS	Primary	≥1	30–50 % (post-BD)

Triple therapy

 Tiotropium + salmeterol + FP [64]	1.37	Tiotropium	1.61	NS	Secondary (any)	≥1	<65 % (post-BD)


Item		Group 1: feedback report (n = 9)	Group 2: feedback report with appendix (n = 11)	P-value

Mean (CI)	Mean (CI)

Scale 1–10	Scale 1–10

1a	I think that the patient safety culture feedback report is....

	 Understandable	6.1 (4.8–7.5)	7.3 (6.0–8.6)	0.04*

	 Interesting	7.6 (7.0–8.1)	7.6 (6.7–8.6)	0.53

	 Useful	6.8 (3.0–7.5)	7.2 (5.8–8.6)	0.10

	 Relevant	7.3 (6.8–7.9)	7.8 (7.3–8.3)	0.20

	 Well-ordered	6.7 (5.9–7.4)	7.5 (6.4–8.5)	0.12

	 Complete	6.9 (6.2–7.6)	7.4 (6.6–8.2)	0.45

	 Attractive (lay-out)	6.8 (6.3–7.3)	7.6 (7.0–8.3)	0.04*

		N (%)	N (%)

2b	Do you miss any results in this report?	5 (56 %)	7 (64 %)

 Yes			1.000

3b	Which statement reflects the patient safety culture report best:	6 (67 %)	5 (46 %)	0.49

 we now see suggestions to improve patient safety culture	1 (11 %)	4 (36 %)

 we now have insight, but we do not know how to improve	2 (22 %)	1 (9 %)

 this report has brought us little new information different statements	-	1 (9 %)


Land-cover type	Proportion of area of suitable habitat (%) 1	Mean habitat suitability (%)

Madrean Encinal	6.3	47.1

Madrean Pinyon-Juniper Woodland	12.6	40.7

Mogollon Chaparral	2.5	38.8

Chihuahuan Mixed Salt Desert Scrub	2.5	34.7

Madrean Lower Montane Pine-Oak Forest and Woodland	1.4	34.6

Apacherian-Chihuahuan Mesquite Upland Scrub	10.6	22.6

Apacherian-Chihuahuan Semi-Desert Grassland and Steppe	28.2	18.9

Chihuahuan Creosote, Mixed Desert and Thorn Scrub	10.4	16.7

Southern Rocky Mountain Ponderosa Pine Woodland	8.5	14.6

Colorado Plateau Pinyon-Juniper Woodland	5.1	13.9

Chihuahuan Stabilized Coppice Dune and Sand Flat Scrub	1.2	8.3

Sonoran Paloverde-Mixed Cacti Desert Scrub	2.8	5.9


Request	Time for the injury prevention request to be responded (ms)

Average	8702.68164

Median	11257


Rank	Topic	Mean	Median

1	Newborn circumcision	1.36	1

2	Reduce paraphimosis	1.36	0

3	Vasectomy	1.18	0

4	Drain hydrocoele	1.00	0

5	Bladder catheterization	0.91	1

6	Intracavernosal injections	0.82	0

7	Adult circumcision	0	0

8	Prostate biopsy	0	0


 	Baseline	Routine clinic visitsa

Fasting plasma glucose	√	√

Fasting insulin	√	√

Glycated haemoglobin A1c	√	√

Serum triglycerides	√	√

Cholesterol	√	√

High-density lipoprotein	√	√

Low-density lipoprotein	√	√

Apolipoprotein B/apolipoprotein A1	√	√

Serum sodium	√	√

Serum potassium	√	√

Serum renin	√	√

Serum osteocalcin	√	√

Serum procollagen I N-terminal propeptide	√	√


 	Group <70 yrs (n)	Group ≥70 yrs (n)

Pulmonary embolism	2	4

Hypertension	6	8

Atrial fibrillation	5	5

Pneumonia	1	2

Leucopenia	4	7

Prolonged ileus	8	10

Urinary tract infections	4	6

Drainage of intra-abdominal collection	2	4

Reoperation	5	3

 Pancreatic fistula	1	1

 Hemorrhage	3	1

 Peritonitis	1	1


Variable	0 min	30 min	60 min	90 min

Heart rate (bpm)Meltdown®	59 ± 3	63 ± 2	62 ± 2	63 ± 2

Heart rate (bpm)Placebo	59 ± 3	60 ± 3	62 ± 3	60 ± 3

Systolic Blood Pressure (mmHg)Meltdown® *	117 ± 2	122 ± 3	123 ± 2	122 ± 3

Systolic Blood Pressure (mmHg)Placebo	118 ± 2	118 ± 2	117 ± 1	116 ± 1

Diastolic Blood Pressure (mmHg)Meltdown®	72 ± 1	71 ± 2	72 ± 2	70 ± 2

Diastolic Blood Pressure (mmHg)Placebo	72 ± 1	72 ± 2	71 ± 1	71 ± 1


Missed appointment	Missed doses	Total

No	Yes

No	694 (94.3)	42 (5.7)	736

Yes	17 (70.8)	7 (29.2)	24


Tag sequence	Tags	TPMa	UniGene ID	Gene	Cluster name	Biological Functionb

TACCTGCAGA	515	16930	Hs.416073	S100A8	S100 calgranulin A	Regulation of cell cycle progression and differentiation.

TAGGTTGTCT	356	11703	Hs.374596	TPT1	Tumor protein, translationally-controlled 1	Unknown

TTTCCTGCTC	276	9073	Hs.139322	SPRR3	Small proline-rich protein 3	Cross-linked envelope protein of keratinocytes

GAGGGAGTTT	201	6607	Hs.523463	RPL27A	Ribosomal protein L27a	Component of the ribosomal 60S subunit

GTGACCACGG	188	6180	Hs.436980	GRIN2C	Glutamate receptor, N-methyl D-aspartate 2C	Ionotropic glutamate receptor

GTGGCCACGG	184	6049	Hs.112405	S100A9	S100 calcium binding protein A9 (calgranulin B)	Regulation of cell cycle progression and differentiation.

GGGCTGGGGT	173	5687	Hs.425125; Hs.90436	RPL29; SPAG7	Ribosomal protein L29; Sperm associated antigen 7	Component of the ribosomal 60S subunit.

GCATAATAGG	168	5523	Hs.381123	RPL21	Ribosomal protein L21	Component of the ribosomal 60S subunit.

TCAGATCTTT	161	5292	Hs.446628	RPS4X	Ribosomal protein S4, X-linked	Component of the ribosomal 40S subunit.

GTTGTGGTTA	155	5095	Hs.99785		FLJ21245	Unknown

GGATTTGGCC	151	4964	Hs.437594	RPLP2	Ribosomal protein, large P2	Component of the ribosomal 60S subunit.

TTGGGGTTTC	143	4701	Hs.448738	FTH1	Ferritin, heavy polypeptide 1	Important for iron homeostasis, stores iron in a soluble, nontoxic, readily available form.

TTGGTCCTCT	138	4536	Hs.381172	RPL41	Rribosomal protein L41	Component of the ribosomal 60S subunit.

TGCACGTTTT	130	4273	Hs.265174	RPL32	Ribosomal protein L32	Component of the ribosomal 60S subunit.

ACAAAGCATT	128	4208	Hs.369982	IGFBP5	Insulin-like growth factor binding protein 5	IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGF on cell culture.

AGGGCTTCCA	122	4010	Hs.401929	RPL10	Ribosomal protein L10	Component of the ribosomal 60S subunit.

CCACTGCACT	114	3747	Hs.107003	CCNB1IP1	Cyclin B1 interacting protein 1	Functions in progression of the cell cycle through G(2)/M.

GGCAAGCCCC	107	3517	Hs.148340	RPL10A	ribosomal protein L10a	Component of the ribosomal 60S subunit.

CTGGGTTAAT	105	3451	Hs.334534	GNS	Glucosamine (N-acetyl)-6-sulfatase	Lysosomal enzyme found in all cells. It is involved in the catabolism of heparin, heparan sulphate, and keratan sulphate.

TGCACTTCAA	103	3386	Hs.62886	SPARCL1	SPARC-like 1 (mast9, hevin)	Calcium ion binding


Variable	Frequency	(%)

Sex

Male	241	54.7 %

Female	199	45.3 %

Age

15-24	89	20.2 %

25-34	112	25.5 %

35-44	85	19.3 %

45-54	65	14.8 %

55-64	49	11.1 %

>64	40	9.1 %

Ethnicity

Oromo	306	69.5 %

Amhara	50	11.5 %

Dawro	43	9.8 %

Othersa	41	9.3 %

Religion

Muslim	332	75.5 %

Orthodox	78	17.7 %

Protestant	30	6.8 %

Educational status

Illiterate	221	50.2 %

Read and write	73	16.6 %

Elementary	113	25.7 %

Secondary education	33	7.5 %

& above

Occupations

Farmers	260	59.1 %

House wives	83	18.9 %

Students	74	16.8 %

Othersb	23	5.2 %


gliomas	Number of cases (tissue cores)

Glioblastoma (GBM, WHO Grade IV)	128 (256)

Anaplastic astrocytoma (AA, WHO Grade III)	27 (54)

Diffuse astrocytoma (LGA, WHO Grade II)	33 (66)

Anaplastic oligodendroglioma (AO, WHO Grade III)	16 (32)

Oligodendroglioma (ODG, WHO Grade II)	26 (52)

Anaplastic mixed oligoastrocytoma (AMOA, WHO Grade III)	30 (60)

Oligoastrocytoma (MOA, WHO Grade II)	32 (64)

non neoplastic brain tissue(NB)	13 (26)


		1	2	3	4	5

1	PTSD – Re-experiencing

2	PTSD – Avoidance	0.48**

3	PTSD – Arousal	0.48**	0.49**

4	DSO – Affect Dysregulation	0.37**	0.40**	0.48**

5	DSO – Disturbances in Self-Concept	0.36**	0.45**	0.46**	0.50**

6	DSO – Difficulties in Interpersonal Relationships	0.27**	0.24**	0.30**	0.47**	0.21*


Complication	Number of complications (%)

Bleeding	10 (3.8)

Aspiration	2 (0.7)

Fistula	2 (0.7)

Wound healing disorders	1 (0.7)

Nerve lesions	3 (1.1)

Other complications	2 (0.7)


Subjectsb	Vbeta	CDR3	BJ	Ratioc

J24 (CD4+)	BV24	AAMYLCATS	SDRVSPL	HFGNGTRLTVTED	1.6	22/25

J23	BV20	SGFYLCAWS	VQVGWGETQ	YFGPGTRLLVLED	2.5	12/21

J24 (CD4+)	BV20	SGFYLCAWS	TGTGHSPL	HFGNGTRLTVTED	1.6	21/25

J28 (CD8+)	BV20	SGFYLCAWS	TGTGHSPL	HFGNGTRLTVTED	1.6	20/24

J38	BV20	SGFYLCAWS	TGTGHSPL	HFGNGTRLTVTED	1.6	22/25

J32 (CD4+)	BV14	SLYFCASS	PGTTQETQ	YFGSGTRLLVLED	2.5	18/23

J25	BV14	SLYFCASS	PGTTQETQ	YFGPGTRLTVLED	2.5	15/23

J28 (CD8+)	BV14	SLYFCASS	RHTGGTEA	FFGQGTRLTVVED	1.1	19/30

J29	BV13.2	TSVYFCASS	YDENEQ	FFGPGTRLTVLED	2.1	16/22

J31 (CD4+)	BV13.2	TSVYFCASK	TKPVGEQ	FFGPGTRLTVLED	2.1	15/23

J42	BV13.1	TSVYFCASS	YSAGGPNEQ	FFGPGTRLTVLED	2.1	18/25

J34 (CD4+)	BV12	TSVYFCAIR	KQGDSYEQ	YFGPGTRLTVTED	2.7	17/23

J35	BV12	TSVYFCASR	VRLITNYGY	TFGSGTRLTVVED	1.2	24/24

J39 (CD4+)	BV12	TSVYFCATA	GGAPGQPQ	HFGDGTRLSILED	1.5	16/24

J23	BJ5.1	SALYLCASS	LDYSGNTI	YFGEGSWLTVVED	1.3	22/27

J25 (CD8+)	BJ5.1	SALYLCASS	LDYSGNTI	YFGEGSWLTVVED	1.3	22/27

J30	BJ5.1	SALYLCASS	LDYSGNTI	YFGEGSWLTVVED	1.3	22/25

J24	BV3	SMYLCASG	PNYYEQ	YFGPGTRLTVTED	2.7	23/25


Activity category	Observed activity	Definition

(1) Nil physical activity	Lying in bed sleeping, talking, reading, eating, watching TV, or doing nothing in particular	Sedentary

(2) Minimal physical activity	Sitting supported out of bed while talking, reading, eating, or doing nothing	Sedentary

(3) Light physical activity	Rolling to sit up, sitting unsupported, or transferring with feet on floor	Physically active

(4) Moderate physical activity	Standing, walking, or climbing stairs	Physically active


AH	Positiona	Lengthb	Hydr. momc	Fract of residuesd	Lipid-binding properties	Ref

Hdr	LH	Ch

Hel 13-5	n.a.e	18	0.69	0.72	0.06	0.28	Tubulates liposomes	73

GMAP210	1–38 (1979)	38	0.48	0.37	0.05	0.05	Golgi vesicles/abundant packing defects	14, 25

Nup133	247–267 (1156)	21	0.44	0.38	0.05	0.10	Nuclear pore membrane	67

CIDEA	163–180 (219)	18	0.53	0.5	0.11	0.17	LDsf	28

CCTα	236–294 (368)	59	0.48*	0.32	0.10	0.49	Nuclear envelope/ER and LDs/liposomes	6, 16,64

Apolipoprotein-AI	74–267 (267)	186 (7 P)g	0.39*	0.40	0.065	0.35	Lipoprotein particles	48

α-Synuclein	1–89 (144)	89	0.30*	0.47	0.02	0.24	Synaptic vesicles/neg. charged small liposomes	44

Plin3	114–204 (434)	90	0.35*	0.37	0.01	0.23	LDs and cytosol	11

Plin4	70–1037 (1357)	968	(0.257)*	0.35	0.002	0.15	This study


Links between mutant GBA and PD	References

Subset of GD patients develop parkinsonism	Bembi et al. (2003), Neudorfer et al. (1996), Tayebi et al. (2001)

Genetic multi-centre study reporting statistically significant association between GBA mutations and PD	Sidransky et al. (2009)

Lewy bodies similar in PD brains with and without GBA mutations	Neumann et al. (2009), Parkkinen et al. (2011)

Accumulation and impaired turnover of α-synuclein in animal and cell models of GCase deficiency	Cullen et al. (2011), Fishbein et al. (2014), Manning-Boğ et al. (2009), Mazzulli et al. (2011), Osellame et al. (2013), Sardi et al. (2011), Schöndorf et al. (2014)

GCase activity decreased in sporadic PD	Gegg et al. (2012), Murphy et al. (2014)

α-synuclein affects GCase function	Gegg et al. (2012), Mazzulli et al. (2011), Sardi et al. (2013), Yap et al. (2011)


Type of atresia	Location	Survival

	Jejunal(n = 11)	Ileal(n = 17)	Survivors(n = 20)	Non-survivors(n = 8)

I	1	1	2	0

II	1	1	0	2

IIIa	2	12	14	0

IIIb	4	1	2	3

IV	3	2	2	3

Total	11	17	20	8


Mediterranean Diet	Paleo Diet

Lipids	Moderate Fat 40% of daily calories	Moderate-Low Fat 35% of daily calories

Proteins	Reduce processed and red meat. Increased plant-based protein, fish and poultry	Reduce processed and red meat. Increased plant-based protein, and meat from marine and game animals

Carbohydrates	Low Carbohydrate ≤40% of daily calories Fruits, vegetables, sugar, and grains	Moderate Carbohydrates ≤45–65% of daily calories Fruits and vegetables Decreased grains


BSS algorithm	Amari indices

Experiment 1:static uncoupled oscillators	Experiment 2: static coupled sources	Experiment 3: dynamic coupled oscillators

AMICA	0.31	0.37	0.25

Extended Infomax	0.31	0.38	0.25

FastICA	0.32	0.30	0.26

PWC-ICA (1)	0.35	0.29	0.28

PWC-ICA (2)	0.34	0.41	0.26

PWC-ICA (4)	0.35	0.41	0.24

PWC-ICA (8)	0.30	0.41	 0.23 (p < 2.3E − 3)

PWC-ICA (1) Haar	0.30	0.32	0.25

PWC-ICA (2) Haar	 0.21 (p < 1.5E − 11)	0.35	 0.23 (p < 4.5E − 4)

PWC-ICA (4) Haar	 0.21 (p < 1.5E − 10)	0.40	 0.23 (p < 4.4E − 2)

PWC-ICA (8) Haar	 0.27 (p < 1.5E − 5)	0.38	0.24

Hilbert complex	 0.28 (p < 1.5E − 4)	0.38	 0.23 (p < 6.7E − 3)

Average baseline	0.36	0.42	0.36


RGT2 mutant designation	Causative constitutive mutation2	Location in Rgt2	Other (likely irrelevant) mutations2

87	F113L	TM1

93	F113L	TM1

58	F113L	TM1	H517R

71	F113L	TM1	T130A, L161S

<underline>82</underline>	D116V	TM1	F562L

68	D116V	TM1	D619G

57	D116G	TM1	I398V, F527L, S754G

100	D116N	TM1	A226T, Y330C

111	D116G, L552S	TM1, ICH5	I111M, V324I, K570R

83	Q222P	TM4

112	Q222R	TM4

RGT2-11	R231K	TM5

98	R231G	TM5	D698G

50	R231G	TM5	M58R

103	G232S	TM5	V537A

<underline>59</underline>	G232S	TM5	F465Y, S733L

86	S236P	TM5	F465Y, G471S

<underline>81</underline>	S236P	TM5	K488R

<underline>493</underline>	S253P, S443P	TM5, TM9

47	D415N	TM8

60	W474R	TM10

95	V475M	TM10

<underline>52</underline>	L552S	ICH5	N723I

85	L552S	ICH5	V404G

1084	V473G?		V473G, D611G, I626V

924	?		G103S, F111L


	H2-Db	H2-Kb	H2-Kk

	Additive Method	SVRMHC Method	Additive Method	SVRMHC Method	Additive Method	SVRMHC Method

Numbers of outliers	6	3	7	6	2	0

r2 (self-consistency, outliers removed)	0.946	0.983	0.989	0.97	0.933	0.973

r2 (self-consistency, entire dataset)	0.602	0.749	0.37	0.568	0.849	0.973

Average Residual (entire dataset)	0.403	0.17	0.443	0.382	0.178	0.039

Average Residual (outliers removed)	0.187	0.043	0.095	0.13	0.151	0.039

q2 (LOO_CV) (outliers removed)	0.401	0.456	0.454	0.486	0.456	0.721


Strain1	Genbank accession #	Experiment location	Strawberry tissue	Closest sequence relatives

Strain(s)	Genbank accession #	Homology %

G1	JN636809	greenhouse	leaf	Candida sp. GA1S07	FJ527144	98

G2*	JN636810	greenhouse	leaf	Cryptococcus sp. VTT C-04547	DQ377668	100

G3	JN636811	greenhouse	leaf	Sakaguchia dacryoidea CBS 6353	AF189973	94

G4	JN636812	greenhouse	leaf	Cryptococcus sp. KCTC 17100	AF459675	100

G5*	JN636813	greenhouse	leaf	Sporobolomyces sp. KCTC 17098	AF459715	95

F1*	JN636806	field	leaf	Cryptococcus sp. HB 982	FM242574	99

F2	JN636807	field	leaf	Cryptococcus heveanensis YFL1.1	HQ629577	99

F3	JN636808	field	ripe fruit	Rhodotorula graminis WP1	EU563930	99

F4*	JN636804	field	unripe fruit	Pichia guilliermondii SYHZS-1	EU809436	100

F5*	JN636805	field	unripe fruit	Metschnikowia pulcherrima Afen	EU272042	95


Watermelon source	Cultivar	(Glucose)(%, w/v)	(Fructose)(%, w/v)	(Sucrose)(%, w/v)	(Amino N)μmol/ml)	(Citrulline)μmol/ml)

2007 Hinton, OK, USA	Crunchy Red	1.4	2.8	3.0	16.3	6.3

2007 Terral, OK, USA	Unknown	2.0	3.6	2.0	33.6	15.4

2008 Louisiana, USA	Summer Flavor 800	1.9	3.5	2.8	33.9	12.6

2008 Lane, OK, USA	Sangria	1.9	3.6	2.8	17.7	5.8

2008 Lane, OK, USA	Dixie Lee	1.7	3.1	1.8	19.9	3.7


Oxidative Stress Genes	Average ΔCt	2 ^ -Δ Ct	Fold Expression

	+DOX	−DOX	+DOX	−DOX	+DOX/− DOX

glutathioneperoxidase2 (GPX2)	8.68	7.06	2.4E-03	7.5E-03	−3.07

peroxidasin (PXDNL)	12.48	10.16	1.8E-04	8.7E-04	−4.99

sulfiredoxin (SRXN1)	6.08	5.06	1.5E-02	3.0E-02	−2.03

peroxiredoxin 2 (PRDX2)	1.68	0.96	3.1E-01	5.1E-01	−1.65

COX2	4.78	4.06	3.6E-02	6.0E-02	−1.65

arachidonate 12-lipoxygenase (12-LOX)	10.08	9.36	9.2E-04	1.5E-03	−1.65

superoxide dismutase 2 (SOD2)	1.08	0.56	4.7E-01	6.8E-01	−1.43*

superoxide dismutase 3 (SOD3)	4.68	4.16	3.9E-02	5.6E-02	−1.43*


Study	Input number	Baseline (%)	FNN	Accuracy (%)	number of subject	Input characteristic

 	 	 	 	multiple linear regression	multiple logistic regression	Case	Healthy control	1 input	2 inputs

Original Study	1 input	63.46	73.88	69.23	73.72	57	99	γ-GTP (IU/L)	−

 	2 inputs	63.71	77.43	75.81	75.81	45	79	γ-GTP (IU/L)	WBC (cells/μL)

Replication Study	1 input	50.00	64.96	64.18	66.44	2196	2196	γ-GTP (IU/L)	−

 	2 inputs	50.00	67.14	66.10	68.53	2196	2196	γ-GTP (IU/L)	WBC (cells/μL)


	Primary aldosteronism N = 158

Source	F statistic	p-value

Age	0.28	0.598

Sex	13.15	<0.001

Hypertension duration	1.98	0.162

Mean blood pressure	5.78	0.018

UAldo, tertile	6.11	0.003

UNa, tertile	7.29	0.001

UAldo*UNa	0.25	0.907


Plant species	Origin	uPA inhibitoryactivity *

Amyris elemifera	Florida, Bahamas, Puerto Rico, West Indies, Central America.	+

Bidens alba L.	Native to South America. Pan tropical weed	−

Cananga odorata	Native to southern Asia and Philippines	+

Capparis cynophallophora	Florida, Bahamas, Puerto Rico, West Indies, Central America.	−

Colubrina elliptica	Puerto Rico, Florida, Bahamas, West Indies, Central Mexico to Venezuela	−

Croton lucidus	Native to PR, Bahamas, Greater Antilles, and Grand Cayman.	+

Erythroxylum areolatum	Bahamas, Greater Antilles, and South America	+

Exostema caribaeum	Florida, Bahamas, West Indies, Mexico, Central America, NE coast South America	−

Guaiacum officinale	Continental Tropical America, PR, West Indies	−

Kalanchoe pinnata	Native to Madagascar	−

Lantana camara	Pantropical	+

Plumeria alba L.	Central America and the Caribbean	−

Tabebuia heterophylla	Puerto Rico, Hispaniola, Virgin Islands, and Lesser Antilles.	+

Vanilla claviculata	Puerto Rico and Greater Antilles	−


GO attribute	No. of genes in category	No. of genes bound by Gcn5p (P value)	No. of genes bound by Sas3p (P value)	No. of genes bound by both (P value)

Cytosolic ribosome	171	43 (3.6 × 10-26)	54 (3.2 × 10-29)	17 (9.4 × 10-16)

Ribosome	284	51 (1.1 × 10-23)	67 (8.6 × 10-28)	21 (6.8 × 10-16)


Gene	#	A	B	C	Gene description	Accession numbers

Symbols	Mean	SD	Mean	SD	Mean	SD

hsp90+	8	5.03*	0.79	0.20*	0.16	0.79	0.15	Heat shock protein 90. beta	NM_198210

fas+	9	4.09*	0.27	0.61*	0.09	1.27	0.16	Fas (TNF receptor superfamily, member 6)	XM_685355

il1b	14	3.71*	0.47	0.42*	0.05	2.05*	0.34	Interleukin 1, beta	NM_212844

hspb+	7	3.51*	0.33	0.52*	0.04	2.27*	0.32	Heat shock protein. alpha-crystalline-related	NM 001008615

Ifih	7	2.78*	0.47	0.48*	0.02	0.78	0.04	Novel protein similar to vertebrate interferon	XM_689032

irf7	8	2.65*	0.17	0.80	0.05	1.29	0.16	Interferon regulatory factor 7	NM_200677

faslg+	11	2.38*	0.28	0.84	0.05	0.91	0.26	Fas ligand (TNF superfamily, member 6)	NM_001042701

casp7+	7	2.23*	0.07	0.55*	0.04	1.36	0.11	Caspase 7, apoptosis cysteine peptidase	NM_001020607

jak1	17	2.21*	0.14	0.76	0.07	1.25	0.12	Janus kinase 1	NM_131073

stat3	13	2.17*	0.24	0.80	0.10	1.18	0.07	Signal transduction/activation transcription 3	XM_002661113

stat1a	23	1.93*	0.15	1.00	0.18	1.21	0.17	Signal transduction/activation transcription 1a	NM_131480

Ikbke	9	1.90*	0.12	0.69	0.03	1.65	0.19	Inhibitor of kappa light polypeptide gene	NM_001002751

Tnfsf	8	1.82*	0.54	0.73	0.21	1.16	0.39	Tumor necrosis factor (ligand) superfamily	NM_001002593

inpp5d	7	1.75*	0.11	0.79	0.01	1.09	0.08	Inositol polyphosphate-5-phosphatase	XM_001922972

irf6	8	0.73	0.12	0.90	0.29	2.15*	0.56	Interferon regulatory factor 6	NM_200598

Igm	7	0.03*	0.01	0.73	0.04	0.51*	0.02	Ig heavy chain constant region home design	AY643753


Patients demographics	N, % (total 30)

Age (mean, SD)	35.6 (9.3)

Gender

 Males	6 (20.0)

 Females	24 (80.0)

Pre-op BMI (mean, SD)	42.8 (5.8)

Diabetes	4 (13.3)

History of smoking	4 (13.3)

Type of bariatric surgery

 Sleeve gastrectomy RYG bypass	28 (93.3)

2 (6.7)


		Significancea

Valence	Percentage	Race/Ethnicity	Gender	Age	Education

Negative	80%	–	–	–	–

Ambivalent or Neutral	30%	*	+	–	–

Positive	59%	–	–	–	–

Not discernible	52%	–	–	–	–


Ingredient:	%

Corn	59.36

SBM, dehulled (48% CP)	33.70

Corn Oil	3.00

Dicalcium phosphate (Technical grade)	1.47

Calcium carbonate (Technical grade)	1.21

Salt, iodized	0.45

DL-methionine	0.21

L-lysine	0.10

Vitamin premix1 (no mineral)	0.25

Mineral premix2 (no Zn)	0.25

Total	100.00

<underline>Calculated (analyzed) nutrients</underline>

ME, kcal/kg	3,080

CP, %	21

Ca3, %	1.00 (1.3)

Nonphytate P3, %	0.45 (0.40)

Lysine, %	1.24

Methionine + Cystein, %	0.90

Zinc (mg/kg)	25


Substrate	Dyad position	Translational shift

 	 	(base pairsa)

S1	74	-

S1-CGG19	72	−2

S1-1AGGa	74.75	+0.75

S1-1AGGb	77.5	+3.5

S1-2AGG	78	+4


Gene or Construct	Accession No:	Primers	Template	Vector

NvStbm (in situ hybridization probe)	1526895:4	Forward 5' CGACAAAGCGAACCAATGTTTACTCT 3'Reverse 5' CCGACATCATGTAAGGGTTATACTCA 3'	Mixed stage N.vectensis cDNA	pGEM

NvStbm (Full-length)	1526895:4	Forward 5'GCCGGAATTCATGCCGCAATATCGTACCAAAGAC 3'Reverse 5' GCCTAGGCCTGACGGAGGTCTCCGAATTTAACTTG 3'	Mixed stage N.vectensis cDNA	pCS2+GFP

NvFz10	XP_001630630	Forward 5' AGTACGATCAGTGCGTCCCCCAATG 3'Reverse 5' CCGCCACGACTTGAATGTTTTTGTAG 3'	Mixed stage N.vectensis cDNA	pGEM

NvFz5	XP_001634995	Forward 5' GCGAAGAGATCACCATTCCCATGTGC 3'Reverse 5' ACCCACCAAACAGAGGAAGCCATTC 3'	Mixed stage N.vectensis cDNA	pGEM

SpAxin	XP_781992	Forward 5' GCCGGAATTCATGAGTCTAGAAGTGTATAGGTTC 3'Reverse 5' GCCGAGGCCTGTGATCATCGACAGATTCCACCTG 3'	Blastula stage S. purpuratus cDNA	pCS2+GFP


Gd-dendrimer generation (G)	Peak concentration in orthotopic RG-2 gliomas (mM)	Peak concentration time point (min)	Peak concentration in ectopic RG-2 gliomas (mM)	Peak concentration time point (min)

Gd-G5	0.147	167	0.195	149

Gd-G6	0.106	200	0.144	189

Gd-G7	0.064	75	0.084	107

Gd-G8	0.049	77	0.052	81


	DVT(n = 9)	PE(n = 9)	AF(n = 13)	Total(n = 31)

COUNTRY (n)

France	3	3	5	11

The Netherlands	3	3	4	10

The United States	3	3	4	10

GENDER (n)

Male	5	2	7	14

Female	4	7	6	17

AGE (years)

Range	21 – 77	30 – 74	39 – 79	21 – 79

Mean	47.4	51.3	68.5	57.4

LIVING SITUATION (n)

Living alone	3	.	5	8

Living as a couple	6	9	8	23

LEVEL OF EDUCATION (n)

Primary school	1	.	3	4

High school diploma	3	3	3	9

Some college or vocational school	1	3	4	8

College or university degree	3	2	1	6

Graduate or professional school	1	1	1	3

Other, please specify	.	.	1 (grammar school)	1

EMPLOYMENT STATUS (n)

Full-time paid employment	4	1	1	6

Part-time paid employment	1*	1*	1	3

Homemaker/housewife	.	1	1	2

Retired	3	3	10	16

Unemployed	.	1	.	1

Not working due to present health status	.	2	.	2

Other, please specify	1 (disabled)	.	.	1


Regions	L/R	MNI (X, Y, Z)	Voxels (mm3)	t-Score

Thalamus	R	14, -30, 10	28	2.9962

Thalamus	L	-12, -28, 9	35	3.6621

Posterior cingulate	R	-13, -50, 16	31	3.5521

Posterior cingulate	L	12, -45, 18	28	2.7536

Angular gyrus	L	-56, -47, 39	35	3.8926

Inferior parietal lobule	L	-50, -27, 25	28	3.6249


GO:BP terms enriched in orthologs differentially expressed exclusively in C. elegans

GO.ID	Term	Annotated	Significant	Expected	p-Value

GO:0018996	molting cycle; collagen and cuticulin-based cuticle.	157	17	4.19	5.70E-07

GO:0040011	locomotion	789	34	21.07	0.0019

GO:0040018	positive regulation of multicellular organism growth	167	11	4.46	0.0046

GO:0006560	proline metabolic process	5	2	0.13	0.0067

GO:0010171	body morphogenesis	322	16	8.6	0.0106

GO:0009084	glutamine family amino acid biosynthesis	8	2	0.21	0.0178

GO:0006694	steroid biosynthetic process	10	2	0.27	0.0277

GO:0055114	oxidation-reduction process	219	11	5.85	0.0306

GO:0006508	proteolysis	197	10	5.26	0.0362

GO:0018991	oviposition	145	8	3.87	0.0387

GO:MF terms enriched in orthologs differentially expressed exclusively in C. elegans

GO.ID	Term	Annotated	Significant	Expected	p-Value

GO:0042302	structural constituent of cuticle	21	10	0.53	1.60E-11

GO:0004222	metalloendopeptidase activity	50	6	1.25	0.0014

GO:0016776	phosphotransferase activity; phosphate group as acceptor	5	2	0.13	0.0059

GO:0016903	oxidoreductase activity; acting on the aldehyde or oxo group of donors	8	2	0.2	0.0157

GO:0003854	3-beta-hydroxy-delta5-steroid dehydrogenase activity	8	2	0.2	0.0157

GO:0019205	nucleobase; nucleoside; nucleotide kinase activity	8	2	0.2	0.0157

GO:0020037	heme binding	51	4	1.28	0.0374

GO:0004601	peroxidase activity	14	2	0.35	0.0464


Characteristics	Patients

8010	8011	8013	8030	8031	8032

Age (years)	50	47	59	69	56	49

Lymphocytosis(×109/L)	6,4	2,5	3,9	2,8	4,4	2,4

Lymphocytosis(% total leukocytosis)	58,4	32,1	36,5	42,5	56,6	48,7

B cells/μL	5250	1550	910	1200	2240	760

Serum IgM(g/L)	12,1	7,8	3,8	9,6	9,5	7,3

Number of BCL-2/Ig rearrangementsa	3 	5 	3 	7 	5 	5

HLA	A 2, 9 B 14, 44Dr 2, 5	A 9, 30 B 13, 14Dr 5, 13	A 9, 39 B 14, 35Dr 5, 13	A 1, 3 B 7, 57Dr 7, 14	ND	A 11, 29 B 35, 44Dr 7, 14

Cigarette smokingb	Yes 	Stopped × 7 years	Yes 	Stopped × 3 years	Yes 	Stopped × 5 years


	Univariate analysis

Factor	Hazard Ratio	p value

Chloroquine treatment	3.28 (1.41-7.63)	0.006

Female	0.93 (0.46-1.91)	0.85

Age (years)	0.96 (0.92-1.00)	0.03

Recruitment site(Jalalabad as reference)

Taloqan	0.79 (0.26-2.43)	0.68

Maimana	3.06 (1.42-6.61)	0.004

Parasitaemia	0.86 (0.32-2.29)	0.76

Presence of gametocytes	1.13 (0.46-2.77)	0.784

Haemoglobin at admission (g/dl)	0.49 (0.37-0.65)	<0.001


Diseases	Genetic variations of TRAFs	References

B cell malignancies

Multiple myeloma	Deletions or inactivating mutations of TRAF3, TRAF2	[294-296]

 	SNPs of TRAF3	[297]

Splenic marginal zone lymphoma	Deletions or inactivating mutations of TRAF3	[298,299]

B cell chronic lymphocytic leukemia	Deletions or inactivating mutations of TRAF3	[298]

Mantle cell lymphoma	Deletions or inactivating mutations of TRAF3	[298]

Waldenström’s macroglobulinemia	Deletions or inactivating mutations of TRAF3	[300]

Hodgkin lymphoma	Deletion of TRAF3	[301]

Diffuse large B-cell lymphoma	Inactivating mutations of TRAF2, TRAF5	[302]

Non-Hodgkin lymphoma	SNPs of TRAF1	[303]

Carcinomas

Breast cancers	Amplification of TRAF4	[304]

Lung cancers	Amplification of TRAF4, TRAF6	[304,305]

Osteosarcoma	Amplification of TRAF6	[306]

Autoimmune diseases

Systemic lupus erythematosus	SNPs of TRAF6, TRAF1/C5	[22,307,308]

Rheumatoid arthritis	SNPs of TRAF5, TRAF6, TRAF1/C5	[22,309-311]

Immunodeficiencies

HSV-1 encephalitis	Inactivating mutation of TRAF3	[312]

Other

Hypohidrotic ectodermal dysplasia	Inactivating mutation of TRAF6	[313]


Category	Variable name	Variable definition

Political Domain	Embassies	Absolute number of in-country embassies and high commissions

	Organizations	Absolute number of memberships in international organizations

	Military	Trade in conventional arms as a share of military spending

Economic domain	Trade	Imports + exports of goods and services as a share of GDP

	FDI	Gross foreign direct stocks as a share of GDP

	Capital	Gross private capital flows as a share of GDP

Social & Cultural Domain	Migrants	Those who changes their country of usual residence per 100 inhabitant

	Tourism	International arrivals + departures per 100 inhabitants

Technological Domain	Phone	Incoming + outgoing international telephone traffic in minutes per capita

	Internet	Internet users as a share of population

Ecological Domain	Eco footprint	Ecological deficit in global ha


Species	Peptide	Ensembl gene ID	Genome assembly	Comment

Coelacanth	NPY	ENSLACG00000001891	LatCha1

Human	NPY	ENSG00000131096	GRCh37

Coelacanth	PYY	ENSLACG00000015096	LatCha1

Human	PYY	ENSG00000131096	GRCh37

Coelacanth	Pancreatic polypeptide	Not annotated in database (JH126680.1:1,154,715–1,154,819)

Human	Pancreatic polypeptide	ENSG00000108849	GRCh37


Database	Type	Species	Method	Entries

Unipep	N-Glycosylated proteins and peptides	Homo sapiens	Hydrazide chemistry & Solid Phase Extraction, in-silico triptic digestion of IPI proteins, and prediction of NXS/T glycosylation site with proteotypic potential	2265

Glycofly	N-Glycosylated proteins and peptides	Drosophila melanogaster	Hydrazide chemistry and Solid Phase Extraction	740

Glycofish	N-Glycosylated proteins and peptides	Danio Rerio	Hydrazide chemistry and Solid Phase Extraction	269

GlycoSuiteDB	O-linked and N-linked Glycoproteins and glycans	 	Published glycoproteins with different methods	9436

GlycoProtDB	N2 and mouse tissues N-Glycoproteins	Caenorhabditis elegans	Lectin Concavilin A Chromatography	1465

Mus Musculus

O-GlycBase NetOGlyc	O and C-Glycosylated proteins	Combination of references	Data curation from literature and coupling ZFN gene targeting, SimpleCell and Lectin Chromatography	2413

3000

dbOGAP	O-GlcNAcylated proteins	Homo Sapiens	Curation from literature and SVM based prediction	798 (exp) 300 (pred)

Mus Musculus

Rattus Norvegicus

Drosophila Melanogaster

Xenopus Laevis


Is it possible to reduce the chance of getting the HIV virus by doing the following?	Yes (n = 171; Male)	Yes (n = 231; Female)

n	%	n	%

Always using a condom	161	94	222	96

Having one uninfected sexual partner	150	87	184	79

Clinical male circumcision	138	80	180	77

Abstinence	145	84	210	90


	Dominant model – infection outcome

APOL1 haplotype	T.b.g Disease	T.b.g Carriage	Association analysis*T.b.g Disease/Carriage

	Number	%	Number	%	OR [95% CI]	P

G1 Haplotype†,‡ rs73885319 (A>G) + rs60910145 (T>G)

G1	36	23.4	25	48.1	0.33 [0.17 to 0.64]	0.0012

Non-G1	118	76.6	27	51.9

Total	154	100.0	52	100.0

G2 Haplotype‡ rs71785313 (TTATAA>del6)

G2	50	31.6	4	7.3	5.87 [2.16 to 20.01]	0.0001

Non-G2	108	68.4	51	92.7

Total	158	100.0	55	100.0


Brain regions	MNI coordinate	BA	Clustersize	T-score

	x	y	z

F–NF

 Medial⋅Superior frontal gyrus	3	33	48	8	17	5.23

 Lt. middle temporal gyrus	−66	−39	−6	21	28	5.21

 Lt. middle temporal gyrus	−63	−36	3	22		4.58

 Lt. inferior frontal gyrus/insula	−39	15	9	45/13	17	4.81

	−30	24	6	45		4.64

 Lt. medial frontal gyrus	−3	36	48	8	12	4.60

NF–F

 No significant activation

E–I

 No significant activation

I–E

 Rt. inferior parietal lobule	42	−54	48	40	10	5.02

 Rt. superior parietal lobule	36	−57	54	7		3.87

(I_F–I_NF)–(E_F–E_NF)

 Rt. superior parietal lobule	27	−57	45	7	33	4.74

 Rt. precuneus	24	−72	51	7		3.37

 Lt. fusiform gyrus	−48	−57	−15	37	10	4.22

 Rt. middle frontal gyrus	48	33	18	46	10	3.70

(E_F–E_NF)–(I_F–I_NF)

 No significant activation


Amino Acid	mg/g Crude Protein	FAO Report mg/g Protein a	AAS

histidine	38.6 ± 2.3	16	2.41

isoleucine	54.5 ± 0.0	30	1.82

leucine	102.1 ± 0.1	61	1.67

lysine	80.2 ± 5.2	48	1.67

threonine	44.3 ± 3.2	25	1.77

tryptophan	6.0 ± 0.0	6.6	0.91

valine	62.4 ± 2.3	40	1.56

methionine	6.4 ± 0.1	-	-

cysteine	24.1 ± 0.0	-	-

SAA	30.5	23	1.33

tyrosine	31.3 ± 1.3	-	-

phenylalanine	76.9 ± 2.0	-	-

AAA	108.2	41	1.88

aspartic acid	146.1 ± 5.1	-	-

serine	68.5 ± 3.5	-	-

glutamic acid	209.5 ± 4.3	-	-

proline	53.6 ± 1.7	-	-

glycine	46.5 ± 3.4	-	-

alanine	51.4 ± 1.4	-	-

arginine	74.8 ± 6.0	-	-

AAS	0.91	-	-

Limiting amino acid	tryptophan	-	-


Name	Company	Catalog number	Antibody concentration

DAB2IP	Abcam	ab87811	1 : 1000 or 1 : 200

E-cadherin	Cell Signaling Technology	3195	1 : 500

Vimentin	Cell Signaling Technology	5741	1 : 500

p-ERK1/2	Cell Signaling Technology	4370	1 : 1000

ERK1/2	Cell Signaling Technology	4695	1 : 1000

GAPDH	Beyotime	AG019	1 : 2000

α-tubulin	Sigma-Aldrich	T6199	1 : 2000


Intentions *	Male (n)	Female (n)

5	4	3	2	1	5	4	3	2	1	p

After the delivery, I would not try to establish breastfeeding. I would bottle-feed my child with formula milk.	0	1	4	13	25	0	3	5	18	85	/

I would breastfeed my child even if the child’s father does not support my decision to breastfeed.	17	19	5	1	1	67	26	10	6	2	/

I would not breastfeed in public, for example in a restaurant or in a park.	9	11	9	8	6	27	26	29	19	10	/

A child’s mother and father should make a joint decision about breastfeeding.	17	15	7	3	1	11	30	33	20	17	0.000

Returning to work would not make me stop breastfeeding.	9	9	23	1	1	40	38	25	5	3	0.002

I find it acceptable to breastfeed after a child turns one if a child so desires.	9	11	11	9	3	17	30	27	24	13	/

I would breastfeed my child in accordance with doctors’ recommendations, regardless of close family members’ opinions.	19	18	5	0	1	38	42	21	8	2	/

I would not breastfeed my child after he/she turns two.	12	13	13	2	3	44	30	27	6	4	/


	Estimate	Standard Error	Chi-Square (df = 1) or t-value	Odds Ratio	95% Confidence Interval	p-value

W1 drinking predicting stroke	-0.31	0.10	10.8	0.73	0.61–0.88	0.001

W1 drinking predicting heart disease	-0.2	0.08	5.8	0.82	0.69–0.96	0.02

W1 drinking predicting diabetes	-0.30	0.13	5.4	0.74	0.57–0.95	0.02

W1 drinking predicting falls	-0.09	0.06	2.5	0.91	0.81–1.02	0.12

W1 drinking predicting hip fracture	-0.42	0.17	5.8	0.66	0.47–0.92	0.02

W1 Drinking predicting % any ADL	-0.22	0.05	19.9	0.80	0.73–0.88	0.0001

W1 Drinking predicting % any IADL	-0.18	0.04	17.3	0.83	0.77–0.91	0.0001

W1 drinking predicting total # Chronic Illnesses	-0.03	0.01	-2.6	---	---	0.01

W1 drinking predicting CES-D	-0.1	0.03	-3.0	---	---	0.01

W1 drinking predicting TICS-R	0.17	0.08	2.14	---	---	0.03


WNV-L vs. E	CHIKV-L vs. E

Symbol	Entrez gene name	Log2 fold change	P-value	Symbol	Entrez gene name	Log2 fold change	P-value

Lcn2	Lipocalin 2	4.87	6.81E-10	Cxcl10	Chemokine (C-X-C motif) ligand 10	5.09	4.38E-13

Cxcl9	Chemokine (C-X-C motif) ligand 9	4.80	4.46E-11	Lcn2	Lipocalin 2	4.73	4.48E-09

Ubd	Ubiquitin D	4.76	2.59E-17	Ccl5	C-C motif chemokine ligand 5	4.19	4.22E-10

Tnfaip2	TNF alpha induced protein 2	4.71	4.00E-13	Ifi204	Interferon activated gene 204	4.18	5.19E-11

Ccl5	C-C motif chemokine ligand 5	4.43	3.01E-11	Gbp2	Guanylate binding protein 2	4.13	1.34E-13

Gzmb	Granzyme B	4.39	4.20E-15	Lilrb4	Leukocyte immunoglobulin like receptor 4	4.12	5.84E-11

Slfn12l	Schlafen family member 12 like	4.07	1.39E-08	Acod1	Aconitate decarboxylase 1	4.08	6.77E-12

Ifnb1	Interferon beta 1	3.89	9.13E-16	Cxcl9	Chemokine (C-X-C motif) ligand 9	4.02	6.94E-09

Ccl13	C-C motif chemokine ligand 13	3.89	1.92E-13	Ms4a4b	Membrane-spanning 4-domains, subfamily A, member 4B	3.99	3.74E-08

Lilrb4	Leukocyte immunoglobulin like receptor B4	3.89	6.82E-11	Tnfaip2	TNF alpha induced protein 2	3.89	1.48E-10


	Pol subtype

Env subtype	A	B	C	D	F	G	H	01_AE	02_AG	UA

A-like	59			3	1	3		1	71	16

B	3	1				4			2	2

C	1		62					1

D				5					1

F					6

G	1					12			5	5

H							1

CRF01AE								57

UA						2			2	8


	Range	Mean (SD)

Temperature, centigrade	36–38	37 ± 0.5

Systolic blood pressure, mmHg	100–190	140 ± 24

Diastolic blood pressure, mmHg	60–140	86 ± 22

Heart rate	66–100	84 ± 11

Respiratory rate	14–26	18 ± 3


Peg	Coupled Score	Abstract Coupling Score	Function

fig|243277.1.peg.316	6	0.38	Translation elongation factor Tu

fig|243277.1.peg.318	39	0.65	Transcription antitermination protein NusG

fig|243277.1.peg.319	24	0.61	LSU ribosomal protein L11p (L12e)

fig|243277.1.peg.320	36	0.64	LSU ribosomal protein L1p (L10Ae)

fig|243277.1.peg.321	11	0.58	LSU ribosomal protein L10p (P0)

fig|243277.1.peg.322	25	0.67	LSU ribosomal protein L7/L12 (L23e)

fig|243277.1.peg.324	34	0.64	DNA-directed RNA polymerase beta' subunit

fig|243277.1.peg.354	-1	0.42	SSU ribosomal protein S12p (S23e)

fig|243277.1.peg.355	-	0.5	SSU ribosomal protein S7p (S5e)

fig|243277.1.peg.4033	-	0.35	Preprotein translocase subunit SecE

fig|243277.1.peg.356	-	0.27	Translation elongation factor G


Component score	SOFA	MOD

Cardiovascular	56%	18%

Respiratory	43%	23%

Coagulation	6%	4%

Renal	0.5%	0.5%

Hepatic	1%	0%


Plan	Plane	6 MV Gamma Passing Rate (%)	Plane	18 MV Gamma Passing Rate (%)

I1 Multitarget	Isocenter	93.9	Isocenter	95.9

I2 Mock Prostate	Isocenter	91.7	Isocenter	91.9

I3 Mock H&N	Isocenter	94.0	Isocenter	95.0

I4 Easy C‐Shape	Isocenter	95.5	Isocenter	89.3

	6 MV Mean	93.8	18 MV Mean	93.3

	6 MV SD	1.6	18 MV SD	3.0

	6 MV CL	9.3	18 MV CL	12.9

	Overall (6 & 18 MV) Mean	93.4

	Overall Standard Deviation	2.3

	Overall Confidence Limit	11.0


RDQ Scale	Effect size	Standardized response mean

	Esomeprazole	Placebo	Esomeprazole	Placebo

Heartburn	2.05	0.85	1.52	0.74

Regurgitation	1.36	0.63	1.31	0.60

Dyspepsia	1.05	0.56	0.99	0.57

GERDa	2.13	0.93	1.68	0.79


Subtypes of epilepsy	T. gondiin (%)	Pvalue	Toxocaran (%)	Pvalue

Idiopathic	16/117 (13.67)	0.8	25/117(21.36)	0.2

Febrile seizure(Special syndrome)	2/10 (20)	0/10(0)

Generalized	2/14 (14.28)	3/14 (21.42)


Anamnestic and clinicalFeatures of red flags	Sign and symptoms ofSpecific shoulder pain

Fever, shivering, changes in body temperature overnight, diaphoresis, nausea, unexplainable sweating overnight, vomiting, sphincteric complaints, diarrhoea, paleness, fatigue, lurching, fainting, exhaustion, excessive and unexplainable weakness, not linked to any physical effort, unexplainable loss of weight, skin rash, unexplainable multiple hematoma, lumps over the body, deformities, inability to lay supine in bed, marked muscle weakness, marked restriction of movement, limb atrophy, local pain and pain during load when age is less than 20 years old and more than 50.	Recent trauma of the shoulder complex, high reactivity of symptoms, pain during the night, limitation of flexion (< 90° both passive and active), apprehension, fear of movement and/or weakness during humeral external rotation.


	ρ	ρ-partial

Baseline disability	0.46‡

Age	0.26‡	0.28‡

Somatization	0.40‡	0.23‡

Depression	0.35‡	0.25‡

Time since onset of pain	0.14†	0.13†

Coping resources	−0.15†	−0.12*

Resilience	−0.21‡	−0.18‡

Gender	0.02	0.08


 	Primary Rd until progression (n=9)	Primary Rd stopped before progression (n=11)	Primary Rd stopped with progression and restarted (n=5)	Rd induction followed by SCT (n=8)

Age, years, median (range)	65 (36–70)	60 (40–78)	55 (32–75)	62 (36–73)

Prior plasma cell disorder, N	6 (3 MGUS/SMM; 3 plasmacytoma)	3 (3 MGUS/SMM)	3 (2 MGUS/SMM; 1 plasmacytoma)	3 (1 MGUS/SMM; 2 plasmacytoma)

MDE at presentation	Bone, 8Anemia, 1	Bone, 10Anemia, 1	Bone, 3Anemia, 1Hypercalcemia, 1	Bone, 7Anemia, 1

Molecular classification, N	Trisomies, 5t(11;14) 1t(11;14) plus trisomy, 1Isolated del 13, 1Normal/insufficient, 1	Trisomies, 6t(11;14), 1Not done, 4	Trisomies, 3Normal/insufficient, 1Not done, 1	Trisomies, 4Isolated del 13, 2Normal/insufficient, 2

Best response to therapy	CR, 7VGPR, 2	CR, 9VGPR, 1 PR, 1	CR, 2VGPR, 2 PR, 1	CR, 7PR, 1


Input	Membership Function

RSSI Level	Weak	Medium	Strong

Number of Neighbours	Low	Medium	High

Distance to each neighbour	Near	Medium	Far


Characteristic (N = 148)	Number	Percent

Gender

 Female	126	85.1

Grade level

 Freshman	36	24.3

 Sophomore	38	25.7

 Junior	39	26.4

 Senior	35	23.6

Experience of dementia education

 Yes	63	42.6

Average time of Experienced education (n = 63)

 Less than 2 h	35	55.6

 More than 2 h	28	44.4

Family member with dementia

 Yes	24	16.2

Experience in caring for persons with dementia

 Yes	63	42.6

Cared for people with dementia during clinical placement

 Yes	62	41.9

Exposure to information on dementia

 Yes	111	75.0

Information sourcesa (n = 111)

 Broadcasting	64	43.2

Educational resources	64	43.2

 Internet	40	27.0

 Family/relatives	24	16.2

 Newspaper	21	14.2

 Magazine	2	1.4

 Others	10	6.8


Scale	Factor	N	%

SCL-90-R	Without psychopathology > 0.99	62	44.6

	Somatization (SOM) > 0.99	47	33.8

	Obsessive-compulsive (OC) > 0.99	43	30.9

	Interpersonal sensitivity (IS) > 0.99	19	13.7

	Depression (DEP) > 0.99	50	36.0

	Anxiety (ANX) > 0.99	33	23.7

	Hostility (HOS) > 0.99	28	20.1

	Phobic anxiety (PHO) > 0.99	18	12.9

	Paranoid ideation (PAR) > 0.99	23	16.5

	Psychoticism (PSY) > 0.99	7	5.0

MQ	Vital exhaustion > 18	71	51.1


Clade	Combined-data and mtDNA	Combined-data and nucDNA	mtDNA and nucDNA

Balistid fish	16%	24%	11%

Scarine fish	83%	63%	50%

Hemiphractid frogs	64%	52%	30%

Hylid frogs	27%	44%	13%

Plethodon salamanders	73%	27%	23%

Phrynosomatid lizards	37%	71%	26%

Alcid birds	91%	33%	23%

Caprimulgid birds	53%	82%	38%

Cotingid birds	53%	71%	35%

Dicaeid birds	80%	34%	24%

Emydid turtles	54%	60%	37%

Cervid mammals	99%	37%	27%

Murid rodents (Philippines)	30%	63%	23%

Murid rodents (Sahul)	55%	96%	53%


Human region	Avian region	Reference

Nucleus accumbens (nAc)	Nucleus accumbens (nAc)	Balint and Csillag (2007), Husband and Shimizu (2011)

Ventral tegmental area (VTA)	Ventral tegmental area (VTA)	Bottjer (1993), Reiner et al. (1994)

Caudate nucleus	Lateral striatum (LSt)	Karten (1969), Reiner et al. (1998)

Hippocampus (Hp)	Hippocampus (Hp)	Erichsen et al. (1991)

Medial amygdala (MeA)	Nucleus taeniae of the amygdala (TnA)	Cheng et al. (1999), Reiner and Karten (1985)

Prefrontal cortex (PFC)	Caudolateral nidopallium (NCL)	Mogensen and Divac (1982), Waldmann and Güntürkün (1993)


	2007	2012

		Exposed to the intervention

		Never	Once	Twice or more	Total	p*	P**

(n = 210)	(n = 63)	(n = 180)

Knowledge of HIV prevention methods	38.8%	59.0%	71.4%	79.4%	68.6%	<10−3	<10−3

Condom use during the most recent sexual encounter with a sex worker	35.5%	40.5%	68.3%	78.5%	60.3%	<10−3	0.34

Systematic condom use with a sex worker in the previous 12 months	12.8%	10.5%	19.0	35.0	21.4%	<10−3	0.38

Voluntary HIV testing and counselling in the previous 12 months	4.3%	6.7%	27.0%	57.8%	29.6%	<10−3	0.20

Knowledge of non-AIDS STI symptoms (men)	24.6%	25.7%	31.7%	36.7%	30.7%	0.02	0.75

Knowledge of non-AIDS STI symptoms (women)	13.4%	9.5%	14.3%	20.0%	14.2%	0.03	0.15

Knowledge that the results of HIV test would remain confidential	23.3%	75.1%	83.9%	92.2%	83.2%	<10−3	<10−3


Study	Type of study	No. of patients receiving short-term radiotherapy (%)	Experimental group^No of DR/No of patients(%)	Control groupNo of DR/No of patients (%)	P value

Nowacki et al. (2004) [4]	Randomized	78 (40.4)	10/97(10.3)	27/96(28.1)	0.002

Collin et al. (2012) [19]	Randomized	54 (100.0)	9/26(34.6)	14/28(50.0)	0.467

Present study	Randomized	162 (100.0)	9/81(11.1)	21/81(25.9)	0.026

Total	–	294 (72.9)	28/204(13.7)	60/205(29.3)	< 0.001